| 21:6.0.1.1.1 | PART 500
| PART 500 - GENERAL | |
| 21:6.0.1.1.1.1 | SUBPART A
| Subpart A [Reserved] | |
| 21:6.0.1.1.1.2 | SUBPART B
| Subpart B - Specific Administrative Rulings and Decisions | |
| 21:6.0.1.1.1.2.1.1 | SECTION 500.23
| 500.23 Thermally processed low-acid foods packaged in hermetically sealed containers. | |
| 21:6.0.1.1.1.2.1.2 | SECTION 500.24
| 500.24 Emergency permit control. | |
| 21:6.0.1.1.1.2.1.3 | SECTION 500.25
| 500.25 Anthelmintic drugs for use in animals. | |
| 21:6.0.1.1.1.2.1.4 | SECTION 500.26
| 500.26 Timed-release dosage form drugs. | |
| 21:6.0.1.1.1.2.1.5 | SECTION 500.27
| 500.27 Methylene blue-containing drugs for use in animals. | |
| 21:6.0.1.1.1.2.1.6 | SECTION 500.29
| 500.29 Gentian violet for use in animal feed. | |
| 21:6.0.1.1.1.2.1.7 | SECTION 500.30
| 500.30 Gentian violet for animal drug use. | |
| 21:6.0.1.1.1.2.1.8 | SECTION 500.45
| 500.45 Use of polychlorinated biphenyls (PCB's) in the production, handling, and storage of animal feed. | |
| 21:6.0.1.1.1.2.1.9 | SECTION 500.46
| 500.46 Hexachlorophene in animal drugs. | |
| 21:6.0.1.1.1.2.1.10 | SECTION 500.50
| 500.50 Propylene glycol in or on cat food. | |
| 21:6.0.1.1.1.3 | SUBPART C
| Subpart C - Animal Drug Labeling Requirements | |
| 21:6.0.1.1.1.3.1.1 | SECTION 500.51
| 500.51 Labeling of animal drugs; misbranding. | |
| 21:6.0.1.1.1.3.1.2 | SECTION 500.52
| 500.52 Use of terms such as “tonic”, “tone”, “toner”, or “conditioner” in the labeling of preparations intended for use in or on animals. | |
| 21:6.0.1.1.1.3.1.3 | SECTION 500.55
| 500.55 Exemption from certain drug-labeling requirements. | |
| 21:6.0.1.1.1.4 | SUBPART D
| Subpart D - Requirements for Specific Animal Drugs | |
| 21:6.0.1.1.1.4.1.1 | SECTION 500.65
| 500.65 Epinephrine injection 1:1,000 in 10-milliliter containers for emergency treatment of anaphylactoid shock in cattle, horses, sheep, and swine. | |
| 21:6.0.1.1.1.5 | SUBPART E
| Subpart E - Regulation of Carcinogenic Compounds Used in Food-Producing Animals | |
| 21:6.0.1.1.1.5.1.1 | SECTION 500.80
| 500.80 Scope of this subpart. | |
| 21:6.0.1.1.1.5.1.2 | SECTION 500.82
| 500.82 Definitions. | |
| 21:6.0.1.1.1.5.1.3 | SECTION 500.84
| 500.84 Conditions for approval of the sponsored compound. | |
| 21:6.0.1.1.1.5.1.4 | SECTION 500.86
| 500.86 Marker residue and target tissue. | |
| 21:6.0.1.1.1.5.1.5 | SECTION 500.88
| 500.88 Regulatory method. | |
| 21:6.0.1.1.1.5.1.6 | SECTION 500.90
| 500.90 Waiver of requirements. | |
| 21:6.0.1.1.1.5.1.7 | SECTION 500.92
| 500.92 Implementation. | |
| 21:6.0.1.1.1.6 | SUBPART F
| Subpart F - Methods for Detection of Residues of Carcinogenic Compounds Used in Food-Producing Animals | |
| 21:6.0.1.1.1.6.1.1 | SECTION 500.1410
| 500.1410 N-methyl-2-pyrrolidone. | |
| 21:6.0.1.1.2 | PART 501
| PART 501 - ANIMAL FOOD LABELING | |
| 21:6.0.1.1.2.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.2.1.1.1 | SECTION 501.1
| 501.1 Principal display panel of package form animal food. | |
| 21:6.0.1.1.2.1.1.2 | SECTION 501.2
| 501.2 Information panel of package for animal food. | |
| 21:6.0.1.1.2.1.1.3 | SECTION 501.3
| 501.3 Identity labeling of animal food in package form. | |
| 21:6.0.1.1.2.1.1.4 | SECTION 501.4
| 501.4 Animal food; designation of ingredients. | |
| 21:6.0.1.1.2.1.1.5 | SECTION 501.5
| 501.5 Animal food; name and place of business of manufacturer, packer, or distributor. | |
| 21:6.0.1.1.2.1.1.6 | SECTION 501.8
| 501.8 Labeling of animal food with number of servings. | |
| 21:6.0.1.1.2.1.1.7 | SECTION 501.15
| 501.15 Animal food; prominence of required statements. | |
| 21:6.0.1.1.2.1.1.8 | SECTION 501.17
| 501.17 Animal food labeling warning statements. | |
| 21:6.0.1.1.2.1.1.9 | SECTION 501.18
| 501.18 Misbranding of animal food. | |
| 21:6.0.1.1.2.2 | SUBPART B
| Subpart B - Specific Animal Food Labeling Requirements | |
| 21:6.0.1.1.2.2.1.1 | SECTION 501.22
| 501.22 Animal foods; labeling of spices, flavorings, colorings, and chemical preservatives. | |
| 21:6.0.1.1.2.3 | SUBPART C
| Subparts C-E [Reserved] | |
| 21:6.0.1.1.2.4 | SUBPART F
| Subpart F - Exemptions From Animal Food Labeling Requirements | |
| 21:6.0.1.1.2.4.1.1 | SECTION 501.100
| 501.100 Animal food; exemptions from labeling. | |
| 21:6.0.1.1.2.4.1.2 | SECTION 501.103
| 501.103 Petitions requesting exemptions from or special requirements for label declaration of ingredients. | |
| 21:6.0.1.1.2.4.1.3 | SECTION 501.105
| 501.105 Declaration of net quantity of contents when exempt. | |
| 21:6.0.1.1.2.4.1.4 | SECTION 501.110
| 501.110 Animal feed labeling; collective names for feed ingredients. | |
| 21:6.0.1.1.3 | PART 502
| PART 502 - COMMON OR USUAL NAMES FOR NONSTANDARDIZED ANIMAL FOODS | |
| 21:6.0.1.1.3.0.1.1 | SECTION 502.5
| 502.5 General principles. | |
| 21:6.0.1.1.3.0.1.2 | SECTION 502.19
| 502.19 Petitions. | |
| 21:6.0.1.1.4 | PART 507
| PART 507 - CURRENT GOOD MANUFACTURING PRACTICE, HAZARD ANALYSIS, AND RISK-BASED PREVENTIVE CONTROLS FOR FOOD FOR ANIMALS | |
| 21:6.0.1.1.4.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.4.1.1.1 | SECTION 507.1
| 507.1 Applicability and status. | |
| 21:6.0.1.1.4.1.1.2 | SECTION 507.3
| 507.3 Definitions. | |
| 21:6.0.1.1.4.1.1.3 | SECTION 507.4
| 507.4 Qualifications of individuals who manufacture, process, pack, or hold animal food. | |
| 21:6.0.1.1.4.1.1.4 | SECTION 507.5
| 507.5 Exemptions. | |
| 21:6.0.1.1.4.1.1.5 | SECTION 507.7
| 507.7 Requirements that apply to a qualified facility. | |
| 21:6.0.1.1.4.1.1.6 | SECTION 507.10
| 507.10 Applicability of subparts C and E of this part to a facility solely engaged in the storage of unexposed packaged animal food. | |
| 21:6.0.1.1.4.1.1.7 | SECTION 507.12
| 507.12 Applicability of this part to the holding and distribution of human food by-products for use as animal food. | |
| 21:6.0.1.1.4.2 | SUBPART B
| Subpart B - Current Good Manufacturing Practice | |
| 21:6.0.1.1.4.2.1.1 | SECTION 507.14
| 507.14 Personnel. | |
| 21:6.0.1.1.4.2.1.2 | SECTION 507.17
| 507.17 Plant and grounds. | |
| 21:6.0.1.1.4.2.1.3 | SECTION 507.19
| 507.19 Sanitation. | |
| 21:6.0.1.1.4.2.1.4 | SECTION 507.20
| 507.20 Water supply and plumbing. | |
| 21:6.0.1.1.4.2.1.5 | SECTION 507.22
| 507.22 Equipment and utensils. | |
| 21:6.0.1.1.4.2.1.6 | SECTION 507.25
| 507.25 Plant operations. | |
| 21:6.0.1.1.4.2.1.7 | SECTION 507.27
| 507.27 Holding and distribution. | |
| 21:6.0.1.1.4.2.1.8 | SECTION 507.28
| 507.28 Holding and distribution of human food by-products for use as animal food. | |
| 21:6.0.1.1.4.3 | SUBPART C
| Subpart C - Hazard Analysis and Risk-Based Preventive Controls | |
| 21:6.0.1.1.4.3.1.1 | SECTION 507.31
| 507.31 Food safety plan. | |
| 21:6.0.1.1.4.3.1.2 | SECTION 507.33
| 507.33 Hazard analysis. | |
| 21:6.0.1.1.4.3.1.3 | SECTION 507.34
| 507.34 Preventive controls. | |
| 21:6.0.1.1.4.3.1.4 | SECTION 507.36
| 507.36 Circumstances in which the owner, operator, or agent in charge of a manufacturing/processing facility is not required to implement a preventive control. | |
| 21:6.0.1.1.4.3.1.5 | SECTION 507.37
| 507.37 Provision of assurances required under § 507.36(a)(2), (3), and (4). | |
| 21:6.0.1.1.4.3.1.6 | SECTION 507.38
| 507.38 Recall plan. | |
| 21:6.0.1.1.4.3.1.7 | SECTION 507.39
| 507.39 Preventive control management components. | |
| 21:6.0.1.1.4.3.1.8 | SECTION 507.40
| 507.40 Monitoring. | |
| 21:6.0.1.1.4.3.1.9 | SECTION 507.42
| 507.42 Corrective actions and corrections. | |
| 21:6.0.1.1.4.3.1.10 | SECTION 507.45
| 507.45 Verification. | |
| 21:6.0.1.1.4.3.1.11 | SECTION 507.47
| 507.47 Validation. | |
| 21:6.0.1.1.4.3.1.12 | SECTION 507.49
| 507.49 Verification of implementation and effectiveness. | |
| 21:6.0.1.1.4.3.1.13 | SECTION 507.50
| 507.50 Reanalysis. | |
| 21:6.0.1.1.4.3.1.14 | SECTION 507.51
| 507.51 Modified requirements that apply to a facility solely engaged in the storage of unexposed packaged animal food. | |
| 21:6.0.1.1.4.3.1.15 | SECTION 507.53
| 507.53 Requirements applicable to a preventive controls qualified individual and a qualified auditor. | |
| 21:6.0.1.1.4.3.1.16 | SECTION 507.55
| 507.55 Implementation records required for this subpart. | |
| 21:6.0.1.1.4.4 | SUBPART D
| Subpart D - Withdrawal of a Qualified Facility Exemption | |
| 21:6.0.1.1.4.4.1.1 | SECTION 507.60
| 507.60 Circumstances that may lead FDA to withdraw a qualified facility exemption. | |
| 21:6.0.1.1.4.4.1.2 | SECTION 507.62
| 507.62 Issuance of an order to withdraw a qualified facility exemption. | |
| 21:6.0.1.1.4.4.1.3 | SECTION 507.65
| 507.65 Contents of an order to withdraw a qualified facility exemption. | |
| 21:6.0.1.1.4.4.1.4 | SECTION 507.67
| 507.67 Compliance with, or appeal of, an order to withdraw a qualified facility exemption. | |
| 21:6.0.1.1.4.4.1.5 | SECTION 507.69
| 507.69 Procedure for submitting an appeal. | |
| 21:6.0.1.1.4.4.1.6 | SECTION 507.71
| 507.71 Procedure for requesting an informal hearing. | |
| 21:6.0.1.1.4.4.1.7 | SECTION 507.73
| 507.73 Requirements applicable to an informal hearing. | |
| 21:6.0.1.1.4.4.1.8 | SECTION 507.75
| 507.75 Presiding officer for an appeal and for an informal hearing. | |
| 21:6.0.1.1.4.4.1.9 | SECTION 507.77
| 507.77 Timeframe for issuing a decision on an appeal. | |
| 21:6.0.1.1.4.4.1.10 | SECTION 507.80
| 507.80 Revocation of an order to withdraw a qualified facility exemption. | |
| 21:6.0.1.1.4.4.1.11 | SECTION 507.83
| 507.83 Final agency action. | |
| 21:6.0.1.1.4.4.1.12 | SECTION 507.85
| 507.85 Reinstatement of a qualified facility exemption that was withdrawn. | |
| 21:6.0.1.1.4.5 | SUBPART E
| Subpart E - Supply-Chain Program | |
| 21:6.0.1.1.4.5.1.1 | SECTION 507.105
| 507.105 Requirement to establish and implement a supply-chain program. | |
| 21:6.0.1.1.4.5.1.2 | SECTION 507.110
| 507.110 General requirements applicable to a supply-chain program. | |
| 21:6.0.1.1.4.5.1.3 | SECTION 507.115
| 507.115 Responsibilities of the receiving facility. | |
| 21:6.0.1.1.4.5.1.4 | SECTION 507.120
| 507.120 Using approved suppliers. | |
| 21:6.0.1.1.4.5.1.5 | SECTION 507.125
| 507.125 Determining appropriate supplier verification activities (including determining the frequency of conducting the activity). | |
| 21:6.0.1.1.4.5.1.6 | SECTION 507.130
| 507.130 Conducting supplier verification activities for raw materials and other ingredients. | |
| 21:6.0.1.1.4.5.1.7 | SECTION 507.135
| 507.135 Onsite audit. | |
| 21:6.0.1.1.4.5.1.8 | SECTION 507.175
| 507.175 Records documenting the supply-chain program. | |
| 21:6.0.1.1.4.6 | SUBPART F
| Subpart F - Requirements Applying to Records That Must Be Established and Maintained | |
| 21:6.0.1.1.4.6.1.1 | SECTION 507.200
| 507.200 Records subject to the requirements of this subpart. | |
| 21:6.0.1.1.4.6.1.2 | SECTION 507.202
| 507.202 General requirements applying to records. | |
| 21:6.0.1.1.4.6.1.3 | SECTION 507.206
| 507.206 Additional requirements applying to the food safety plan. | |
| 21:6.0.1.1.4.6.1.4 | SECTION 507.208
| 507.208 Requirements for record retention. | |
| 21:6.0.1.1.4.6.1.5 | SECTION 507.212
| 507.212 Use of existing records. | |
| 21:6.0.1.1.4.6.1.6 | SECTION 507.215
| 507.215 Special requirements applicable to a written assurance. | |
| 21:6.0.1.1.5 | PART 509
| PART 509 - UNAVOIDABLE CONTAMINANTS IN ANIMAL FOOD AND FOOD-PACKAGING MATERIAL | |
| 21:6.0.1.1.5.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.5.1.1.1 | SECTION 509.3
| 509.3 Definitions and interpretations. | |
| 21:6.0.1.1.5.1.1.2 | SECTION 509.4
| 509.4 Establishment of tolerances, regulatory limits, and action levels. | |
| 21:6.0.1.1.5.1.1.3 | SECTION 509.5
| 509.5 Petitions. | |
| 21:6.0.1.1.5.1.1.4 | SECTION 509.6
| 509.6 Added poisonous or deleterious substances. | |
| 21:6.0.1.1.5.1.1.5 | SECTION 509.7
| 509.7 Unavoidability. | |
| 21:6.0.1.1.5.1.1.6 | SECTION 509.15
| 509.15 Use of polychlorinated biphenyls (PCB's) in establishments manufacturing food-packaging materials. | |
| 21:6.0.1.1.5.2 | SUBPART B
| Subpart B - Tolerances for Unavoidable Poisonous or Deleterious Substances | |
| 21:6.0.1.1.5.2.1.1 | SECTION 509.30
| 509.30 Temporary tolerances for polychlorinated biphenyls (PCB's). | |
| 21:6.0.1.1.5.3 | SUBPART C
| Subpart C - Regulatory Limits for Added Poisonous or Deleterious Substances [Reserved] | |
| 21:6.0.1.1.5.4 | SUBPART D
| Subpart D - Naturally Occurring Poisonous or Deleterious Substances [Reserved] | |
| 21:6.0.1.1.6 | PART 510
| PART 510 - NEW ANIMAL DRUGS | |
| 21:6.0.1.1.6.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.6.1.1.1 | SECTION 510.3
| 510.3 Definitions and interpretations. | |
| 21:6.0.1.1.6.1.1.2 | SECTION 510.4
| 510.4 Biologics; products subject to license control. | |
| 21:6.0.1.1.6.1.1.3 | SECTION 510.7
| 510.7 Consignees of new animal drugs for use in the manufacture of animal feed. | |
| 21:6.0.1.1.6.1.1.4 | SECTION 510.95
| 510.95 [Reserved] | |
| 21:6.0.1.1.6.2 | SUBPART B
| Subpart B - Specific Administrative Rulings and Decisions | |
| 21:6.0.1.1.6.2.1.1 | SECTION 510.105
| 510.105 Labeling of drugs for use in milk-producing animals. | |
| 21:6.0.1.1.6.2.1.2 | SECTION 510.106
| 510.106 Labeling of antibiotic and antibiotic-containing drugs intended for use in milk-producing animals. | |
| 21:6.0.1.1.6.2.1.3 | SECTION 510.110
| 510.110 Antibiotics used in food-producing animals. | |
| 21:6.0.1.1.6.2.1.4 | SECTION 510.112
| 510.112 Antibiotics used in veterinary medicine and for nonmedical purposes; required data. | |
| 21:6.0.1.1.6.3 | SUBPART C
| Subpart C [Reserved] | |
| 21:6.0.1.1.6.4 | SUBPART D
| Subpart D - Records and Reports | |
| 21:6.0.1.1.6.4.1.1 | SECTION 510.301
| 510.301 Records and reports concerning experience with animal feeds bearing or containing new animal drugs for which an approved medicated feed mill license application is in effect. | |
| 21:6.0.1.1.6.4.1.2 | SECTION 510.305
| 510.305 Maintenance of copies of approved medicated feed mill licenses to manufacture animal feed bearing or containing new animal drugs. | |
| 21:6.0.1.1.6.5 | SUBPART E
| Subpart E - Requirements for Specific New Animal Drugs | |
| 21:6.0.1.1.6.5.1.1 | SECTION 510.410
| 510.410 Corticosteroids for oral, injectable, and ophthalmic use in animals; warnings and labeling requirements. | |
| 21:6.0.1.1.6.5.1.2 | SECTION 510.440
| 510.440 Injectable iron preparations. | |
| 21:6.0.1.1.6.5.1.3 | SECTION 510.455
| 510.455 Requirements for free-choice medicated feeds. | |
| 21:6.0.1.1.6.6 | SUBPART F
| Subpart F [Reserved] | |
| 21:6.0.1.1.6.7 | SUBPART G
| Subpart G - Sponsors of Approved Applications | |
| 21:6.0.1.1.6.7.1.1 | SECTION 510.600
| 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications. | |
| 21:6.0.1.1.7 | PART 511
| PART 511 - NEW ANIMAL DRUGS FOR INVESTIGATIONAL USE | |
| 21:6.0.1.1.7.0.1.1 | SECTION 511.1
| 511.1 New animal drugs for investigational use exempt from section 512(a) of the Federal Food, Drug, and Cosmetic Act. | |
| 21:6.0.1.1.7.0.1.2 | SECTION 511.3
| 511.3 Definitions. | |
| 21:6.0.1.1.8 | PART 514
| PART 514 - NEW ANIMAL DRUG APPLICATIONS | |
| 21:6.0.1.1.8.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.8.1.1.1 | SECTION 514.1
| 514.1 Applications. | |
| 21:6.0.1.1.8.1.1.2 | SECTION 514.3
| 514.3 Definitions. | |
| 21:6.0.1.1.8.1.1.3 | SECTION 514.4
| 514.4 Substantial evidence. | |
| 21:6.0.1.1.8.1.1.4 | SECTION 514.5
| 514.5 Presubmission conferences. | |
| 21:6.0.1.1.8.1.1.5 | SECTION 514.6
| 514.6 Amended applications. | |
| 21:6.0.1.1.8.1.1.6 | SECTION 514.7
| 514.7 Withdrawal of applications without prejudice. | |
| 21:6.0.1.1.8.1.1.7 | SECTION 514.8
| 514.8 Supplements and other changes to an approved application. | |
| 21:6.0.1.1.8.1.1.8 | SECTION 514.11
| 514.11 Confidentiality of data and information in a new animal drug application file. | |
| 21:6.0.1.1.8.1.1.9 | SECTION 514.12
| 514.12 Confidentiality of data and information in an investigational new animal drug notice. | |
| 21:6.0.1.1.8.1.1.10 | SECTION 514.15
| 514.15 Untrue statements in applications. | |
| 21:6.0.1.1.8.2 | SUBPART B
| Subpart B - Administrative Actions on Applications | |
| 21:6.0.1.1.8.2.1.1 | SECTION 514.80
| 514.80 Records and reports concerning experience with approved new animal drugs. | |
| 21:6.0.1.1.8.2.1.2 | SECTION 514.87
| 514.87 Annual reports for antimicrobial animal drug sales and distribution. | |
| 21:6.0.1.1.8.2.1.3 | SECTION 514.100
| 514.100 Evaluation and comment on applications. | |
| 21:6.0.1.1.8.2.1.4 | SECTION 514.105
| 514.105 Approval of applications. | |
| 21:6.0.1.1.8.2.1.5 | SECTION 514.106
| 514.106 Approval of supplemental applications. | |
| 21:6.0.1.1.8.2.1.6 | SECTION 514.110
| 514.110 Reasons for refusing to file applications. | |
| 21:6.0.1.1.8.2.1.7 | SECTION 514.111
| 514.111 Refusal to approve an application. | |
| 21:6.0.1.1.8.2.1.8 | SECTION 514.115
| 514.115 Withdrawal of approval of applications. | |
| 21:6.0.1.1.8.2.1.9 | SECTION 514.116
| 514.116 Notice of withdrawal of approval of application. | |
| 21:6.0.1.1.8.2.1.10 | SECTION 514.117
| 514.117 Adequate and well-controlled studies. | |
| 21:6.0.1.1.8.2.1.11 | SECTION 514.120
| 514.120 Revocation of order refusing to approve an application or suspending or withdrawing approval of an application. | |
| 21:6.0.1.1.8.2.1.12 | SECTION 514.121
| 514.121 Service of notices and orders. | |
| 21:6.0.1.1.8.3 | SUBPART C
| Subpart C - Hearing Procedures | |
| 21:6.0.1.1.8.3.1.1 | SECTION 514.200
| 514.200 Notice of opportunity for hearing; notice of participation and requests for hearing; grant or denial of hearing. | |
| 21:6.0.1.1.8.3.1.2 | SECTION 514.201
| 514.201 Procedures for hearings. | |
| 21:6.0.1.1.8.4 | SUBPART D
| Subparts D-E [Reserved] | |
| 21:6.0.1.1.8.5 | SUBPART F
| Subpart F - Judicial Review | |
| 21:6.0.1.1.8.5.1.1 | SECTION 514.235
| 514.235 Judicial review. | |
| 21:6.0.1.1.9 | PART 515
| PART 515 - MEDICATED FEED MILL LICENSE | |
| 21:6.0.1.1.9.1 | SUBPART A
| Subpart A - Applications | |
| 21:6.0.1.1.9.1.1.1 | SECTION 515.10
| 515.10 Medicated feed mill license applications. | |
| 21:6.0.1.1.9.1.1.2 | SECTION 515.11
| 515.11 Supplemental medicated feed mill license applications. | |
| 21:6.0.1.1.9.2 | SUBPART B
| Subpart B - Administrative Actions on Licenses | |
| 21:6.0.1.1.9.2.1.1 | SECTION 515.20
| 515.20 Approval of medicated feed mill license applications. | |
| 21:6.0.1.1.9.2.1.2 | SECTION 515.21
| 515.21 Refusal to approve a medicated feed mill license application. | |
| 21:6.0.1.1.9.2.1.3 | SECTION 515.22
| 515.22 Suspension and/or revocation of approval of a medicated feed mill license. | |
| 21:6.0.1.1.9.2.1.4 | SECTION 515.23
| 515.23 Voluntary revocation of medicated feed mill license. | |
| 21:6.0.1.1.9.2.1.5 | SECTION 515.24
| 515.24 Notice of revocation of a medicated feed mill license. | |
| 21:6.0.1.1.9.2.1.6 | SECTION 515.25
| 515.25 Revocation of order refusing to approve a medicated feed mill license application or suspending or revoking a license. | |
| 21:6.0.1.1.9.2.1.7 | SECTION 515.26
| 515.26 Services of notices and orders. | |
| 21:6.0.1.1.9.3 | SUBPART C
| Subpart C - Hearing Procedures | |
| 21:6.0.1.1.9.3.1.1 | SECTION 515.30
| 515.30 Contents of notice of opportunity for a hearing. | |
| 21:6.0.1.1.9.3.1.2 | SECTION 515.31
| 515.31 Procedures for hearings. | |
| 21:6.0.1.1.9.4 | SUBPART D
| Subpart D - Judicial Review | |
| 21:6.0.1.1.9.4.1.1 | SECTION 515.40
| 515.40 Judicial review. | |
| 21:6.0.1.1.10 | PART 516
| PART 516 - NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES | |
| 21:6.0.1.1.10.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.10.1.1.1 | SECTION 516.1
| 516.1 Scope. | |
| 21:6.0.1.1.10.1.1.2 | SECTION 516.2
| 516.2 Purpose. | |
| 21:6.0.1.1.10.1.1.3 | SECTION 516.3
| 516.3 Definitions. | |
| 21:6.0.1.1.10.2 | SUBPART B
| Subpart B - Designation of a Minor Use or Minor Species New Animal Drug | |
| 21:6.0.1.1.10.2.1.1 | SECTION 516.11
| 516.11 Scope of this subpart. | |
| 21:6.0.1.1.10.2.1.2 | SECTION 516.12
| 516.12 Purpose. | |
| 21:6.0.1.1.10.2.1.3 | SECTION 516.13
| 516.13 Definitions. | |
| 21:6.0.1.1.10.2.1.4 | SECTION 516.14
| 516.14 Submission of requests for designation. | |
| 21:6.0.1.1.10.2.1.5 | SECTION 516.16
| 516.16 Eligibility to request designation. | |
| 21:6.0.1.1.10.2.1.6 | SECTION 516.20
| 516.20 Content and format of a request for MUMS-drug designation. | |
| 21:6.0.1.1.10.2.1.7 | SECTION 516.21
| 516.21 Documentation of minor use status. | |
| 21:6.0.1.1.10.2.1.8 | SECTION 516.22
| 516.22 Permanent-resident U.S. agent for foreign sponsor. | |
| 21:6.0.1.1.10.2.1.9 | SECTION 516.23
| 516.23 Timing of requests for MUMS-drug designation. | |
| 21:6.0.1.1.10.2.1.10 | SECTION 516.24
| 516.24 Granting MUMS-drug designation. | |
| 21:6.0.1.1.10.2.1.11 | SECTION 516.25
| 516.25 Refusal to grant MUMS-drug designation. | |
| 21:6.0.1.1.10.2.1.12 | SECTION 516.26
| 516.26 Amendment to MUMS-drug designation. | |
| 21:6.0.1.1.10.2.1.13 | SECTION 516.27
| 516.27 Change in sponsorship. | |
| 21:6.0.1.1.10.2.1.14 | SECTION 516.28
| 516.28 Publication of MUMS-drug designations. | |
| 21:6.0.1.1.10.2.1.15 | SECTION 516.29
| 516.29 Termination of MUMS-drug designation. | |
| 21:6.0.1.1.10.2.1.16 | SECTION 516.30
| 516.30 Annual reports for a MUMS-designated drug. | |
| 21:6.0.1.1.10.2.1.17 | SECTION 516.31
| 516.31 Scope of MUMS-drug exclusive marketing rights. | |
| 21:6.0.1.1.10.2.1.18 | SECTION 516.34
| 516.34 FDA recognition of exclusive marketing rights. | |
| 21:6.0.1.1.10.2.1.19 | SECTION 516.36
| 516.36 Insufficient quantities of MUMS-designated drugs. | |
| 21:6.0.1.1.10.2.1.20 | SECTION 516.52
| 516.52 Availability for public disclosure of data and information in requests. | |
| 21:6.0.1.1.10.3 | SUBPART C
| Subpart C - Index of Legally Marketed Unapproved New Animal Drugs for Minor Species | |
| 21:6.0.1.1.10.3.1.1 | SECTION 516.111
| 516.111 Scope of this subpart. | |
| 21:6.0.1.1.10.3.1.2 | SECTION 516.115
| 516.115 Definitions. | |
| 21:6.0.1.1.10.3.1.3 | SECTION 516.117
| 516.117 Submission of correspondence under this subpart. | |
| 21:6.0.1.1.10.3.1.4 | SECTION 516.119
| 516.119 Permanent-resident U.S. agent for foreign requestors and holders. | |
| 21:6.0.1.1.10.3.1.5 | SECTION 516.121
| 516.121 Meetings. | |
| 21:6.0.1.1.10.3.1.6 | SECTION 516.123
| 516.123 Informal conferences regarding agency administrative actions. | |
| 21:6.0.1.1.10.3.1.7 | SECTION 516.125
| 516.125 Investigational use of minor species new animal drugs to support indexing. | |
| 21:6.0.1.1.10.3.1.8 | SECTION 516.129
| 516.129 Content and format of a request for determination of eligibility for indexing. | |
| 21:6.0.1.1.10.3.1.9 | SECTION 516.131
| 516.131 Refuse to file a request for determination of eligibility for indexing. | |
| 21:6.0.1.1.10.3.1.10 | SECTION 516.133
| 516.133 Denying a request for determination of eligibility for indexing. | |
| 21:6.0.1.1.10.3.1.11 | SECTION 516.135
| 516.135 Granting a request for determination of eligibility for indexing. | |
| 21:6.0.1.1.10.3.1.12 | SECTION 516.137
| 516.137 Notification of decision regarding eligibility for indexing. | |
| 21:6.0.1.1.10.3.1.13 | SECTION 516.141
| 516.141 Qualified expert panels. | |
| 21:6.0.1.1.10.3.1.14 | SECTION 516.143
| 516.143 Written report. | |
| 21:6.0.1.1.10.3.1.15 | SECTION 516.145
| 516.145 Content and format of a request for addition to the index. | |
| 21:6.0.1.1.10.3.1.16 | SECTION 516.147
| 516.147 Refuse to file a request for addition to the index. | |
| 21:6.0.1.1.10.3.1.17 | SECTION 516.149
| 516.149 Denying a request for addition to the index. | |
| 21:6.0.1.1.10.3.1.18 | SECTION 516.151
| 516.151 Granting a request for addition to the index. | |
| 21:6.0.1.1.10.3.1.19 | SECTION 516.153
| 516.153 Notification of decision regarding index listing. | |
| 21:6.0.1.1.10.3.1.20 | SECTION 516.155
| 516.155 Labeling of indexed drugs. | |
| 21:6.0.1.1.10.3.1.21 | SECTION 516.157
| 516.157 Publication of the index and content of an index listing. | |
| 21:6.0.1.1.10.3.1.22 | SECTION 516.161
| 516.161 Modifications to indexed drugs. | |
| 21:6.0.1.1.10.3.1.23 | SECTION 516.163
| 516.163 Change in ownership of an index file. | |
| 21:6.0.1.1.10.3.1.24 | SECTION 516.165
| 516.165 Records and reports. | |
| 21:6.0.1.1.10.3.1.25 | SECTION 516.167
| 516.167 Removal from the index. | |
| 21:6.0.1.1.10.3.1.26 | SECTION 516.171
| 516.171 Confidentiality of data and information in an index file. | |
| 21:6.0.1.1.10.4 | SUBPART D
| Subpart D [Reserved] | |
| 21:6.0.1.1.10.5 | SUBPART E
| Subpart E - Conditionally Approved New Animal Drugs For Minor Use and Minor Species | |
| 21:6.0.1.1.10.5.1.1 | SECTION 516.1684
| 516.1684 Paclitaxel. | |
| 21:6.0.1.1.10.5.1.2 | SECTION 516.2065
| 516.2065 Rabacfosadine. | |
| 21:6.0.1.1.11 | PART 520
| PART 520 - ORAL DOSAGE FORM NEW ANIMAL DRUGS | |
| 21:6.0.1.1.11.0.1.1 | SECTION 520.23
| 520.23 Acepromazine. | |
| 21:6.0.1.1.11.0.1.2 | SECTION 520.28
| 520.28 Acetazolamide. | |
| 21:6.0.1.1.11.0.1.3 | SECTION 520.38
| 520.38 Albendazole oral dosage forms. | |
| 21:6.0.1.1.11.0.1.4 | SECTION 520.38a
| 520.38a Albendazole suspension. | |
| 21:6.0.1.1.11.0.1.5 | SECTION 520.38b
| 520.38b Albendazole paste. | |
| 21:6.0.1.1.11.0.1.6 | SECTION 520.43
| 520.43 Afoxolaner. | |
| 21:6.0.1.1.11.0.1.7 | SECTION 520.48
| 520.48 Altrenogest. | |
| 21:6.0.1.1.11.0.1.8 | SECTION 520.62
| 520.62 Aminopentamide. | |
| 21:6.0.1.1.11.0.1.9 | SECTION 520.82
| 520.82 Aminopropazine oral dosage forms. | |
| 21:6.0.1.1.11.0.1.10 | SECTION 520.82a
| 520.82a Aminopropazine. | |
| 21:6.0.1.1.11.0.1.11 | SECTION 520.82b
| 520.82b Aminopropazine and neomycin. | |
| 21:6.0.1.1.11.0.1.12 | SECTION 520.88
| 520.88 Amoxicillin oral dosage forms. | |
| 21:6.0.1.1.11.0.1.13 | SECTION 520.88a
| 520.88a Amoxicillin trihydrate film-coated tablets. | |
| 21:6.0.1.1.11.0.1.14 | SECTION 520.88b
| 520.88b Amoxicillin trihydrate for oral suspension. | |
| 21:6.0.1.1.11.0.1.15 | SECTION 520.88c
| 520.88c Amoxicillin trihydrate oral suspension. | |
| 21:6.0.1.1.11.0.1.16 | SECTION 520.88d
| 520.88d Amoxicillin trihydrate soluble powder. | |
| 21:6.0.1.1.11.0.1.17 | SECTION 520.88e
| 520.88e Amoxicillin trihydrate boluses. | |
| 21:6.0.1.1.11.0.1.18 | SECTION 520.88f
| 520.88f Amoxicillin trihydrate tablets. | |
| 21:6.0.1.1.11.0.1.19 | SECTION 520.88g
| 520.88g Amoxicillin trihydrate and clavulanate potassium tablets. | |
| 21:6.0.1.1.11.0.1.20 | SECTION 520.88h
| 520.88h Amoxicillin trihydrate and clavulanate potassium for oral suspension. | |
| 21:6.0.1.1.11.0.1.21 | SECTION 520.90
| 520.90 Ampicillin oral dosage forms. | |
| 21:6.0.1.1.11.0.1.22 | SECTION 520.90a
| 520.90a Ampicillin tablets. | |
| 21:6.0.1.1.11.0.1.23 | SECTION 520.90b
| 520.90b Ampicillin capsules. | |
| 21:6.0.1.1.11.0.1.24 | SECTION 520.90c
| 520.90c Ampicillin boluses. | |
| 21:6.0.1.1.11.0.1.25 | SECTION 520.100
| 520.100 Amprolium. | |
| 21:6.0.1.1.11.0.1.26 | SECTION 520.110
| 520.110 Apramycin sulfate soluble powder. | |
| 21:6.0.1.1.11.0.1.27 | SECTION 520.154
| 520.154 Bacitracin oral dosage forms. | |
| 21:6.0.1.1.11.0.1.28 | SECTION 520.154a
| 520.154a Bacitracin methylenedisalicylate. | |
| 21:6.0.1.1.11.0.1.29 | SECTION 520.154b
| 520.154b Bacitracin methylenedisalicylate and streptomycin sulfate powder. | |
| 21:6.0.1.1.11.0.1.30 | SECTION 520.154c
| 520.154c Bacitracin zinc soluble powder. | |
| 21:6.0.1.1.11.0.1.31 | SECTION 520.222
| 520.222 Bunamidine hydrochloride. | |
| 21:6.0.1.1.11.0.1.32 | SECTION 520.246
| 520.246 Butorphanol tablets. | |
| 21:6.0.1.1.11.0.1.33 | SECTION 520.260
| 520.260 n-Butyl chloride. | |
| 21:6.0.1.1.11.0.1.34 | SECTION 520.284
| 520.284 Cambendazole oral dosage forms. | |
| 21:6.0.1.1.11.0.1.35 | SECTION 520.284a
| 520.284a Cambendazole suspension. | |
| 21:6.0.1.1.11.0.1.36 | SECTION 520.284b
| 520.284b Cambendazole pellets. | |
| 21:6.0.1.1.11.0.1.37 | SECTION 520.284c
| 520.284c Cambendazole paste. | |
| 21:6.0.1.1.11.0.1.38 | SECTION 520.292
| 520.292 Capromorelin. | |
| 21:6.0.1.1.11.0.1.39 | SECTION 520.301
| 520.301 Caramiphen ethanedisulfonate and ammonium chloride tablets. | |
| 21:6.0.1.1.11.0.1.40 | SECTION 520.302
| 520.302 Carnidazole tablets. | |
| 21:6.0.1.1.11.0.1.41 | SECTION 520.304
| 520.304 Carprofen. | |
| 21:6.0.1.1.11.0.1.42 | SECTION 520.314
| 520.314 Cefadroxil. | |
| 21:6.0.1.1.11.0.1.43 | SECTION 520.370
| 520.370 Cefpodoxime tablets. | |
| 21:6.0.1.1.11.0.1.44 | SECTION 520.376
| 520.376 Cephalexin. | |
| 21:6.0.1.1.11.0.1.45 | SECTION 520.390
| 520.390 Chloramphenicol oral dosage forms. | |
| 21:6.0.1.1.11.0.1.46 | SECTION 520.390a
| 520.390a Chloramphenicol tablets. | |
| 21:6.0.1.1.11.0.1.47 | SECTION 520.390b
| 520.390b Chloramphenicol capsules. | |
| 21:6.0.1.1.11.0.1.48 | SECTION 520.390c
| 520.390c Chloramphenicol palmitate oral suspension. | |
| 21:6.0.1.1.11.0.1.49 | SECTION 520.420
| 520.420 Chlorothiazide. | |
| 21:6.0.1.1.11.0.1.50 | SECTION 520.434
| 520.434 Chlorphenesin carbamate tablets. | |
| 21:6.0.1.1.11.0.1.51 | SECTION 520.441
| 520.441 Chlortetracycline powder. | |
| 21:6.0.1.1.11.0.1.52 | SECTION 520.443
| 520.443 Chlortetracycline tablets and boluses. | |
| 21:6.0.1.1.11.0.1.53 | SECTION 520.445
| 520.445 Chlortetracycline and sulfamethazine powder. | |
| 21:6.0.1.1.11.0.1.54 | SECTION 520.446
| 520.446 Clindamycin capsules and tablets. | |
| 21:6.0.1.1.11.0.1.55 | SECTION 520.447
| 520.447 Clindamycin solution. | |
| 21:6.0.1.1.11.0.1.56 | SECTION 520.452
| 520.452 Clenbuterol syrup. | |
| 21:6.0.1.1.11.0.1.57 | SECTION 520.455
| 520.455 Clomipramine tablets. | |
| 21:6.0.1.1.11.0.1.58 | SECTION 520.462
| 520.462 Clorsulon drench. | |
| 21:6.0.1.1.11.0.1.59 | SECTION 520.522
| 520.522 Cyclosporine. | |
| 21:6.0.1.1.11.0.1.60 | SECTION 520.530
| 520.530 Cythioate oral liquid. | |
| 21:6.0.1.1.11.0.1.61 | SECTION 520.531
| 520.531 Cythioate tablets. | |
| 21:6.0.1.1.11.0.1.62 | SECTION 520.534
| 520.534 Decoquinate. | |
| 21:6.0.1.1.11.0.1.63 | SECTION 520.538
| 520.538 Deracoxib. | |
| 21:6.0.1.1.11.0.1.64 | SECTION 520.540
| 520.540 Dexamethasone oral dosage forms. | |
| 21:6.0.1.1.11.0.1.65 | SECTION 520.540a
| 520.540a Dexamethasone powder. | |
| 21:6.0.1.1.11.0.1.66 | SECTION 520.540b
| 520.540b Dexamethasone tablets and boluses. | |
| 21:6.0.1.1.11.0.1.67 | SECTION 520.540c
| 520.540c Dexamethasone chewable tablets. | |
| 21:6.0.1.1.11.0.1.68 | SECTION 520.563
| 520.563 Dexamethasone chewable tablets. | |
| 21:6.0.1.1.11.0.1.69 | SECTION 520.580
| 520.580 Dichlorophene and toluene. | |
| 21:6.0.1.1.11.0.1.70 | SECTION 520.581
| 520.581 Dichlorophene tablets. | |
| 21:6.0.1.1.11.0.1.71 | SECTION 520.596
| 520.596 Dichlorvos powder. | |
| 21:6.0.1.1.11.0.1.72 | SECTION 520.598
| 520.598 Dichlorvos tablets. | |
| 21:6.0.1.1.11.0.1.73 | SECTION 520.600
| 520.600 Dichlorvos capsules and pellets. | |
| 21:6.0.1.1.11.0.1.74 | SECTION 520.602
| 520.602 Dichlorvos gel. | |
| 21:6.0.1.1.11.0.1.75 | SECTION 520.606
| 520.606 Diclazuril. | |
| 21:6.0.1.1.11.0.1.76 | SECTION 520.608
| 520.608 Dicloxacillin. | |
| 21:6.0.1.1.11.0.1.77 | SECTION 520.620
| 520.620 Diethylcarbamazine oral dosage forms. | |
| 21:6.0.1.1.11.0.1.78 | SECTION 520.622
| 520.622 Diethylcarbamazine citrate oral dosage forms. | |
| 21:6.0.1.1.11.0.1.79 | SECTION 520.622a
| 520.622a Diethylcarbamazine citrate tablets. | |
| 21:6.0.1.1.11.0.1.80 | SECTION 520.622b
| 520.622b Diethylcarbamazine citrate syrup. | |
| 21:6.0.1.1.11.0.1.81 | SECTION 520.622c
| 520.622c Diethylcarbamazine citrate chewable tablets. | |
| 21:6.0.1.1.11.0.1.82 | SECTION 520.623
| 520.623 Diethylcarbamazine and oxibendazole chewable tablets. | |
| 21:6.0.1.1.11.0.1.83 | SECTION 520.645
| 520.645 Difloxacin. | |
| 21:6.0.1.1.11.0.1.84 | SECTION 520.666
| 520.666 Dirlotapide. | |
| 21:6.0.1.1.11.0.1.85 | SECTION 520.763
| 520.763 Dithiazanine oral dosage forms. | |
| 21:6.0.1.1.11.0.1.86 | SECTION 520.763a
| 520.763a Dithiazanine tablets. | |
| 21:6.0.1.1.11.0.1.87 | SECTION 520.763b
| 520.763b Dithiazanine powder. | |
| 21:6.0.1.1.11.0.1.88 | SECTION 520.763c
| 520.763c Dithiazanine iodide and piperazine citrate suspension. | |
| 21:6.0.1.1.11.0.1.89 | SECTION 520.766
| 520.766 Domperidone. | |
| 21:6.0.1.1.11.0.1.90 | SECTION 520.784
| 520.784 Doxylamine. | |
| 21:6.0.1.1.11.0.1.91 | SECTION 520.804
| 520.804 Enalapril. | |
| 21:6.0.1.1.11.0.1.92 | SECTION 520.812
| 520.812 Enrofloxacin. | |
| 21:6.0.1.1.11.0.1.93 | SECTION 520.816
| 520.816 Epsiprantel. | |
| 21:6.0.1.1.11.0.1.94 | SECTION 520.823
| 520.823 Erythromycin. | |
| 21:6.0.1.1.11.0.1.95 | SECTION 520.852
| 520.852 Estriol. | |
| 21:6.0.1.1.11.0.1.96 | SECTION 520.863
| 520.863 Ethylisobutrazine. | |
| 21:6.0.1.1.11.0.1.97 | SECTION 520.870
| 520.870 Etodolac. | |
| 21:6.0.1.1.11.0.1.98 | SECTION 520.903
| 520.903 Febantel oral dosage forms. | |
| 21:6.0.1.1.11.0.1.99 | SECTION 520.903a
| 520.903a Febantel paste. | |
| 21:6.0.1.1.11.0.1.100 | SECTION 520.903b
| 520.903b Febantel suspension. | |
| 21:6.0.1.1.11.0.1.101 | SECTION 520.903c
| 520.903c Febantel and praziquantel paste. | |
| 21:6.0.1.1.11.0.1.102 | SECTION 520.903d
| 520.903d Febantel tablets. | |
| 21:6.0.1.1.11.0.1.103 | SECTION 520.905
| 520.905 Fenbendazole oral dosage forms. | |
| 21:6.0.1.1.11.0.1.104 | SECTION 520.905a
| 520.905a Fenbendazole suspension. | |
| 21:6.0.1.1.11.0.1.105 | SECTION 520.905b
| 520.905b Fenbendazole granules. | |
| 21:6.0.1.1.11.0.1.106 | SECTION 520.905c
| 520.905c Fenbendazole paste. | |
| 21:6.0.1.1.11.0.1.107 | SECTION 520.905d
| 520.905d Fenbendazole powder. | |
| 21:6.0.1.1.11.0.1.108 | SECTION 520.905e
| 520.905e Fenbendazole blocks. | |
| 21:6.0.1.1.11.0.1.109 | SECTION 520.928
| 520.928 Firocoxib tablets. | |
| 21:6.0.1.1.11.0.1.110 | SECTION 520.930
| 520.930 Firocoxib paste. | |
| 21:6.0.1.1.11.0.1.111 | SECTION 520.955
| 520.955 Florfenicol. | |
| 21:6.0.1.1.11.0.1.112 | SECTION 520.960
| 520.960 Flumethasone. | |
| 21:6.0.1.1.11.0.1.113 | SECTION 520.970
| 520.970 Flunixin. | |
| 21:6.0.1.1.11.0.1.114 | SECTION 520.980
| 520.980 Fluoxetine. | |
| 21:6.0.1.1.11.0.1.115 | SECTION 520.998
| 520.998 Fluralaner. | |
| 21:6.0.1.1.11.0.1.116 | SECTION 520.1010
| 520.1010 Furosemide. | |
| 21:6.0.1.1.11.0.1.117 | SECTION 520.1044
| 520.1044 Gentamicin sulfate oral dosage forms. | |
| 21:6.0.1.1.11.0.1.118 | SECTION 520.1044a
| 520.1044a Gentamicin sulfate oral solution. | |
| 21:6.0.1.1.11.0.1.119 | SECTION 520.1044b
| 520.1044b Gentamicin sulfate pig pump oral solution. | |
| 21:6.0.1.1.11.0.1.120 | SECTION 520.1044c
| 520.1044c Gentamicin sulfate powder. | |
| 21:6.0.1.1.11.0.1.121 | SECTION 520.1060
| 520.1060 Glucose and glycine. | |
| 21:6.0.1.1.11.0.1.122 | SECTION 520.1084
| 520.1084 Grapiprant. | |
| 21:6.0.1.1.11.0.1.123 | SECTION 520.1100
| 520.1100 Griseofulvin. | |
| 21:6.0.1.1.11.0.1.124 | SECTION 520.1120
| 520.1120 Haloxon oral dosage forms. | |
| 21:6.0.1.1.11.0.1.125 | SECTION 520.1120a
| 520.1120a Haloxon drench. | |
| 21:6.0.1.1.11.0.1.126 | SECTION 520.1120b
| 520.1120b Haloxon boluses. | |
| 21:6.0.1.1.11.0.1.127 | SECTION 520.1130
| 520.1130 Hetacillin. | |
| 21:6.0.1.1.11.0.1.128 | SECTION 520.1150
| 520.1150 Imepitoin. | |
| 21:6.0.1.1.11.0.1.129 | SECTION 520.1156
| 520.1156 Imidacloprid. | |
| 21:6.0.1.1.11.0.1.130 | SECTION 520.1157
| 520.1157 Iodinated casein. | |
| 21:6.0.1.1.11.0.1.131 | SECTION 520.1158
| 520.1158 Iodochlorhydroxyquin. | |
| 21:6.0.1.1.11.0.1.132 | SECTION 520.1189
| 520.1189 Itraconazole. | |
| 21:6.0.1.1.11.0.1.133 | SECTION 520.1192
| 520.1192 Ivermectin paste. | |
| 21:6.0.1.1.11.0.1.134 | SECTION 520.1193
| 520.1193 Ivermectin tablets and chewables. | |
| 21:6.0.1.1.11.0.1.135 | SECTION 520.1194
| 520.1194 Ivermectin meal. | |
| 21:6.0.1.1.11.0.1.136 | SECTION 520.1195
| 520.1195 Ivermectin liquid. | |
| 21:6.0.1.1.11.0.1.137 | SECTION 520.1196
| 520.1196 Ivermectin and pyrantel tablets. | |
| 21:6.0.1.1.11.0.1.138 | SECTION 520.1197
| 520.1197 Ivermectin sustained-release bolus. | |
| 21:6.0.1.1.11.0.1.139 | SECTION 520.1198
| 520.1198 Ivermectin and praziquantel paste. | |
| 21:6.0.1.1.11.0.1.140 | SECTION 520.1199
| 520.1199 Ivermectin, pyrantel, and praziquantel tablets. | |
| 21:6.0.1.1.11.0.1.141 | SECTION 520.1200
| 520.1200 Ivermectin, fenbendazole, and praziquantel tablets. | |
| 21:6.0.1.1.11.0.1.142 | SECTION 520.1204
| 520.1204 Kanamycin, bismuth subcarbonate, activated attapulgite. | |
| 21:6.0.1.1.11.0.1.143 | SECTION 520.1242
| 520.1242 Levamisole. | |
| 21:6.0.1.1.11.0.1.144 | SECTION 520.1242a
| 520.1242a Levamisole powder. | |
| 21:6.0.1.1.11.0.1.145 | SECTION 520.1242b
| 520.1242b Levamisol boluses or oblets. | |
| 21:6.0.1.1.11.0.1.146 | SECTION 520.1242c
| 520.1242c Levamisol and piperazine. | |
| 21:6.0.1.1.11.0.1.147 | SECTION 520.1242d
| 520.1242d Levamisole resinate. | |
| 21:6.0.1.1.11.0.1.148 | SECTION 520.1242e
| 520.1242e Levamisole hydrochloride effervescent tablets. | |
| 21:6.0.1.1.11.0.1.149 | SECTION 520.1242f
| 520.1242f Levamisol gel. | |
| 21:6.0.1.1.11.0.1.150 | SECTION 520.1242g
| 520.1242g Levamisole resinate and famphur paste. | |
| 21:6.0.1.1.11.0.1.151 | SECTION 520.1248
| 520.1248 Levothyroxine. | |
| 21:6.0.1.1.11.0.1.152 | SECTION 520.1263
| 520.1263 Lincomycin. | |
| 21:6.0.1.1.11.0.1.153 | SECTION 520.1263a
| 520.1263a Lincomycin tablets and syrup. | |
| 21:6.0.1.1.11.0.1.154 | SECTION 520.1263b
| 520.1263b Lincomycin powder. | |
| 21:6.0.1.1.11.0.1.155 | SECTION 520.1265
| 520.1265 Lincomycin and spectinomycin powder. | |
| 21:6.0.1.1.11.0.1.156 | SECTION 520.1284
| 520.1284 Liothyronine. | |
| 21:6.0.1.1.11.0.1.157 | SECTION 520.1286
| 520.1286 Lotilaner. | |
| 21:6.0.1.1.11.0.1.158 | SECTION 520.1288
| 520.1288 Lufenuron tablets. | |
| 21:6.0.1.1.11.0.1.159 | SECTION 520.1289
| 520.1289 Lufenuron suspension. | |
| 21:6.0.1.1.11.0.1.160 | SECTION 520.1310
| 520.1310 Marbofloxacin. | |
| 21:6.0.1.1.11.0.1.161 | SECTION 520.1315
| 520.1315 Maropitant. | |
| 21:6.0.1.1.11.0.1.162 | SECTION 520.1320
| 520.1320 Mebendazole. | |
| 21:6.0.1.1.11.0.1.163 | SECTION 520.1326
| 520.1326 Mebendazole and trichlorfon oral dosage forms. | |
| 21:6.0.1.1.11.0.1.164 | SECTION 520.1326a
| 520.1326a Mebendazole and trichlorfon powder. | |
| 21:6.0.1.1.11.0.1.165 | SECTION 520.1326b
| 520.1326b Mebendazole and trichlorfon paste. | |
| 21:6.0.1.1.11.0.1.166 | SECTION 520.1330
| 520.1330 Meclofenamic acid granules. | |
| 21:6.0.1.1.11.0.1.167 | SECTION 520.1331
| 520.1331 Meclofenamic acid tablets. | |
| 21:6.0.1.1.11.0.1.168 | SECTION 520.1341
| 520.1341 Megestrol. | |
| 21:6.0.1.1.11.0.1.169 | SECTION 520.1367
| 520.1367 Meloxicam. | |
| 21:6.0.1.1.11.0.1.170 | SECTION 520.1372
| 520.1372 Methimazole. | |
| 21:6.0.1.1.11.0.1.171 | SECTION 520.1380
| 520.1380 Methocarbamol. | |
| 21:6.0.1.1.11.0.1.172 | SECTION 520.1408
| 520.1408 Methylprednisolone. | |
| 21:6.0.1.1.11.0.1.173 | SECTION 520.1409
| 520.1409 Methylprednisolone and aspirin. | |
| 21:6.0.1.1.11.0.1.174 | SECTION 520.1422
| 520.1422 Metoserpate hydrochloride. | |
| 21:6.0.1.1.11.0.1.175 | SECTION 520.1430
| 520.1430 Mibolerone. | |
| 21:6.0.1.1.11.0.1.176 | SECTION 520.1441
| 520.1441 Milbemycin. | |
| 21:6.0.1.1.11.0.1.177 | SECTION 520.1443
| 520.1443 Milbemycin oxime and lufenuron. | |
| 21:6.0.1.1.11.0.1.178 | SECTION 520.1445
| 520.1445 Milbemycin oxime and praziquantel. | |
| 21:6.0.1.1.11.0.1.179 | SECTION 520.1447
| 520.1447 Milbemycin oxime, lufenuron, and praziquantel tablets. | |
| 21:6.0.1.1.11.0.1.180 | SECTION 520.1450
| 520.1450 Morantel tartrate oral dosage forms. | |
| 21:6.0.1.1.11.0.1.181 | SECTION 520.1450a
| 520.1450a Morantel tartrate bolus. | |
| 21:6.0.1.1.11.0.1.182 | SECTION 520.1450b
| 520.1450b Morantel tartrate cartridge. | |
| 21:6.0.1.1.11.0.1.183 | SECTION 520.1450c
| 520.1450c Morantel tartrate sustained-release trilaminate cylinder/sheet. | |
| 21:6.0.1.1.11.0.1.184 | SECTION 520.1451
| 520.1451 Moxidectin tablets. | |
| 21:6.0.1.1.11.0.1.185 | SECTION 520.1452
| 520.1452 Moxidectin gel. | |
| 21:6.0.1.1.11.0.1.186 | SECTION 520.1453
| 520.1453 Moxidectin and praziquantel gel. | |
| 21:6.0.1.1.11.0.1.187 | SECTION 520.1454
| 520.1454 Moxidectin solution. | |
| 21:6.0.1.1.11.0.1.188 | SECTION 520.1468
| 520.1468 Naproxen. | |
| 21:6.0.1.1.11.0.1.189 | SECTION 520.1484
| 520.1484 Neomycin. | |
| 21:6.0.1.1.11.0.1.190 | SECTION 520.1510
| 520.1510 Nitenpyram. | |
| 21:6.0.1.1.11.0.1.191 | SECTION 520.1604
| 520.1604 Oclacitinib. | |
| 21:6.0.1.1.11.0.1.192 | SECTION 520.1615
| 520.1615 Omeprazole. | |
| 21:6.0.1.1.11.0.1.193 | SECTION 520.1616
| 520.1616 Orbifloxacin tablets. | |
| 21:6.0.1.1.11.0.1.194 | SECTION 520.1618
| 520.1618 Orbifloxacin suspension. | |
| 21:6.0.1.1.11.0.1.195 | SECTION 520.1628
| 520.1628 Oxfendazole powder and pellets. | |
| 21:6.0.1.1.11.0.1.196 | SECTION 520.1629
| 520.1629 Oxfendazole paste. | |
| 21:6.0.1.1.11.0.1.197 | SECTION 520.1630
| 520.1630 Oxfendazole suspension. | |
| 21:6.0.1.1.11.0.1.198 | SECTION 520.1631
| 520.1631 Oxfendazole and trichlorfon paste. | |
| 21:6.0.1.1.11.0.1.199 | SECTION 520.1638
| 520.1638 Oxibendazole. | |
| 21:6.0.1.1.11.0.1.200 | SECTION 520.1660
| 520.1660 Oxytetracycline. | |
| 21:6.0.1.1.11.0.1.201 | SECTION 520.1660a
| 520.1660a Oxytetracycline and carbomycin. | |
| 21:6.0.1.1.11.0.1.202 | SECTION 520.1660b
| 520.1660b Oxytetracycline hydrochloride capsules. | |
| 21:6.0.1.1.11.0.1.203 | SECTION 520.1660c
| 520.1660c Oxytetracycline hydrochloride tablets/boluses. | |
| 21:6.0.1.1.11.0.1.204 | SECTION 520.1660d
| 520.1660d Oxytetracycline powder. | |
| 21:6.0.1.1.11.0.1.205 | SECTION 520.1696
| 520.1696 Penicillin. | |
| 21:6.0.1.1.11.0.1.206 | SECTION 520.1696a
| 520.1696a Penicillin G powder. | |
| 21:6.0.1.1.11.0.1.207 | SECTION 520.1696b
| 520.1696b Penicillin V powder. | |
| 21:6.0.1.1.11.0.1.208 | SECTION 520.1696c
| 520.1696c Penicillin V tablets. | |
| 21:6.0.1.1.11.0.1.209 | SECTION 520.1705
| 520.1705 Pergolide. | |
| 21:6.0.1.1.11.0.1.210 | SECTION 520.1720
| 520.1720 Phenylbutazone oral dosage forms. | |
| 21:6.0.1.1.11.0.1.211 | SECTION 520.1720a
| 520.1720a Phenylbutazone tablets and boluses. | |
| 21:6.0.1.1.11.0.1.212 | SECTION 520.1720b
| 520.1720b Phenylbutazone granules. | |
| 21:6.0.1.1.11.0.1.213 | SECTION 520.1720c
| 520.1720c Phenylbutazone paste. | |
| 21:6.0.1.1.11.0.1.214 | SECTION 520.1720d
| 520.1720d Phenylbutazone gel. | |
| 21:6.0.1.1.11.0.1.215 | SECTION 520.1720e
| 520.1720e Phenylbutazone powder. | |
| 21:6.0.1.1.11.0.1.216 | SECTION 520.1760
| 520.1760 Phenylpropanolamine. | |
| 21:6.0.1.1.11.0.1.217 | SECTION 520.1780
| 520.1780 Pimobendan. | |
| 21:6.0.1.1.11.0.1.218 | SECTION 520.1802
| 520.1802 Piperazine-carbon disulfide complex oral dosage forms. | |
| 21:6.0.1.1.11.0.1.219 | SECTION 520.1802a
| 520.1802a Piperazine-carbon disulfide complex suspension. | |
| 21:6.0.1.1.11.0.1.220 | SECTION 520.1802b
| 520.1802b Piperazine-carbon disulfide complex boluses. | |
| 21:6.0.1.1.11.0.1.221 | SECTION 520.1802c
| 520.1802c Piperazine-carbon disulfide complex with phenothiazine suspension. | |
| 21:6.0.1.1.11.0.1.222 | SECTION 520.1803
| 520.1803 Piperazine citrate capsules. | |
| 21:6.0.1.1.11.0.1.223 | SECTION 520.1805
| 520.1805 Piperazine phosphate with thenium closylate tablets. | |
| 21:6.0.1.1.11.0.1.224 | SECTION 520.1806
| 520.1806 Piperazine suspension. | |
| 21:6.0.1.1.11.0.1.225 | SECTION 520.1840
| 520.1840 Poloxalene. | |
| 21:6.0.1.1.11.0.1.226 | SECTION 520.1846
| 520.1846 Polyoxyethylene (23) lauryl ether blocks. | |
| 21:6.0.1.1.11.0.1.227 | SECTION 520.1855
| 520.1855 Ponazuril. | |
| 21:6.0.1.1.11.0.1.228 | SECTION 520.1860
| 520.1860 Pradofloxacin. | |
| 21:6.0.1.1.11.0.1.229 | SECTION 520.1870
| 520.1870 Praziquantel tablets. | |
| 21:6.0.1.1.11.0.1.230 | SECTION 520.1871
| 520.1871 Praziquantel and pyrantel. | |
| 21:6.0.1.1.11.0.1.231 | SECTION 520.1872
| 520.1872 Praziquantel, pyrantel pamoate, and febantel tablets. | |
| 21:6.0.1.1.11.0.1.232 | SECTION 520.1880
| 520.1880 Prednisolone. | |
| 21:6.0.1.1.11.0.1.233 | SECTION 520.1900
| 520.1900 Primidone. | |
| 21:6.0.1.1.11.0.1.234 | SECTION 520.1920
| 520.1920 Prochlorperazine and isopropamide. | |
| 21:6.0.1.1.11.0.1.235 | SECTION 520.1921
| 520.1921 Prochlorperazine, isopropamide, and neomycin. | |
| 21:6.0.1.1.11.0.1.236 | SECTION 520.1962
| 520.1962 Promazine. | |
| 21:6.0.1.1.11.0.1.237 | SECTION 520.2002
| 520.2002 Propiopromazine. | |
| 21:6.0.1.1.11.0.1.238 | SECTION 520.2041
| 520.2041 Pyrantel pamoate chewable tablets. | |
| 21:6.0.1.1.11.0.1.239 | SECTION 520.2042
| 520.2042 Pyrantel pamoate tablets. | |
| 21:6.0.1.1.11.0.1.240 | SECTION 520.2043
| 520.2043 Pyrantel pamoate suspension. | |
| 21:6.0.1.1.11.0.1.241 | SECTION 520.2044
| 520.2044 Pyrantel pamoate paste. | |
| 21:6.0.1.1.11.0.1.242 | SECTION 520.2045
| 520.2045 Pyrantel tartrate powder. | |
| 21:6.0.1.1.11.0.1.243 | SECTION 520.2046
| 520.2046 Pyrantel tartrate pellets. | |
| 21:6.0.1.1.11.0.1.244 | SECTION 520.2075
| 520.2075 Robenacoxib. | |
| 21:6.0.1.1.11.0.1.245 | SECTION 520.2086
| 520.2086 Sarolaner. | |
| 21:6.0.1.1.11.0.1.246 | SECTION 520.2090
| 520.2090 Sarolaner, moxidectin, and pyrantel. | |
| 21:6.0.1.1.11.0.1.247 | SECTION 520.2098
| 520.2098 Selegiline. | |
| 21:6.0.1.1.11.0.1.248 | SECTION 520.2100
| 520.2100 Selenium and vitamin E. | |
| 21:6.0.1.1.11.0.1.249 | SECTION 520.2123
| 520.2123 Spectinomycin oral dosage forms. | |
| 21:6.0.1.1.11.0.1.250 | SECTION 520.2123a
| 520.2123a Spectinomycin tablets. | |
| 21:6.0.1.1.11.0.1.251 | SECTION 520.2123b
| 520.2123b Spectinomycin powder. | |
| 21:6.0.1.1.11.0.1.252 | SECTION 520.2123c
| 520.2123c Spectinomycin solution. | |
| 21:6.0.1.1.11.0.1.253 | SECTION 520.2130
| 520.2130 Spinosad. | |
| 21:6.0.1.1.11.0.1.254 | SECTION 520.2134
| 520.2134 Spinosad and milbemycin. | |
| 21:6.0.1.1.11.0.1.255 | SECTION 520.2150
| 520.2150 Stanozolol. | |
| 21:6.0.1.1.11.0.1.256 | SECTION 520.2158
| 520.2158 Streptomycin. | |
| 21:6.0.1.1.11.0.1.257 | SECTION 520.2170
| 520.2170 Sulfabromomethazine. | |
| 21:6.0.1.1.11.0.1.258 | SECTION 520.2184
| 520.2184 Sulfachloropyrazine. | |
| 21:6.0.1.1.11.0.1.259 | SECTION 520.2200
| 520.2200 Sulfachlorpyridazine. | |
| 21:6.0.1.1.11.0.1.260 | SECTION 520.2215
| 520.2215 Sulfadiazine/pyrimethamine suspension. | |
| 21:6.0.1.1.11.0.1.261 | SECTION 520.2218
| 520.2218 Sulfamerazine, sulfamethazine, and sulfaquinoxaline powder. | |
| 21:6.0.1.1.11.0.1.262 | SECTION 520.2220
| 520.2220 Sulfadimethoxine oral dosage forms. | |
| 21:6.0.1.1.11.0.1.263 | SECTION 520.2220a
| 520.2220a Sulfadimethoxine oral solution and soluble powder. | |
| 21:6.0.1.1.11.0.1.264 | SECTION 520.2220b
| 520.2220b Sulfadimethoxine suspension. | |
| 21:6.0.1.1.11.0.1.265 | SECTION 520.2220c
| 520.2220c Sulfadimethoxine tablet. | |
| 21:6.0.1.1.11.0.1.266 | SECTION 520.2220d
| 520.2220d Sulfadimethoxine bolus. | |
| 21:6.0.1.1.11.0.1.267 | SECTION 520.2220e
| 520.2220e Sulfadimethoxine extended-release bolus. | |
| 21:6.0.1.1.11.0.1.268 | SECTION 520.2220f
| 520.2220f Sulfadimethoxine and ormetoprim tablet. | |
| 21:6.0.1.1.11.0.1.269 | SECTION 520.2240
| 520.2240 Sulfaethoxypyridazine. | |
| 21:6.0.1.1.11.0.1.270 | SECTION 520.2240a
| 520.2240a Sulfaethoxypyridazine solution. | |
| 21:6.0.1.1.11.0.1.271 | SECTION 520.2240b
| 520.2240b Sulfaethoxypyridazine tablets. | |
| 21:6.0.1.1.11.0.1.272 | SECTION 520.2260
| 520.2260 Sulfamethazine oral dosage forms. | |
| 21:6.0.1.1.11.0.1.273 | SECTION 520.2260a
| 520.2260a Sulfamethazine oblet, tablet, and bolus. | |
| 21:6.0.1.1.11.0.1.274 | SECTION 520.2260b
| 520.2260b Sulfamethazine sustained-release boluses. | |
| 21:6.0.1.1.11.0.1.275 | SECTION 520.2260c
| 520.2260c Sulfamethazine sustained-release tablets. | |
| 21:6.0.1.1.11.0.1.276 | SECTION 520.2261
| 520.2261 Sulfamethazine sodium oral dosage forms. | |
| 21:6.0.1.1.11.0.1.277 | SECTION 520.2261a
| 520.2261a Sulfamethazine solution. | |
| 21:6.0.1.1.11.0.1.278 | SECTION 520.2261b
| 520.2261b Sulfamethazine powder. | |
| 21:6.0.1.1.11.0.1.279 | SECTION 520.2280
| 520.2280 Sulfamethizole and methenamine. | |
| 21:6.0.1.1.11.0.1.280 | SECTION 520.2325
| 520.2325 Sulfaquinoxaline oral dosage forms. | |
| 21:6.0.1.1.11.0.1.281 | SECTION 520.2325a
| 520.2325a Sulfaquinoxaline powder and solution. | |
| 21:6.0.1.1.11.0.1.282 | SECTION 520.2325b
| 520.2325b Sulfaquinoxaline drench. | |
| 21:6.0.1.1.11.0.1.283 | SECTION 520.2330
| 520.2330 Sulfisoxazole tablets. | |
| 21:6.0.1.1.11.0.1.284 | SECTION 520.2335
| 520.2335 Telmisartan. | |
| 21:6.0.1.1.11.0.1.285 | SECTION 520.2340
| 520.2340 Tepoxalin. | |
| 21:6.0.1.1.11.0.1.286 | SECTION 520.2345
| 520.2345 Tetracycline. | |
| 21:6.0.1.1.11.0.1.287 | SECTION 520.2345a
| 520.2345a Tetracycline capsules. | |
| 21:6.0.1.1.11.0.1.288 | SECTION 520.2345b
| 520.2345b Tetracycline tablets. | |
| 21:6.0.1.1.11.0.1.289 | SECTION 520.2345c
| 520.2345c Tetracycline boluses. | |
| 21:6.0.1.1.11.0.1.290 | SECTION 520.2345d
| 520.2345d Tetracycline powder. | |
| 21:6.0.1.1.11.0.1.291 | SECTION 520.2345e
| 520.2345e Tetracycline solution. | |
| 21:6.0.1.1.11.0.1.292 | SECTION 520.2345f
| 520.2345f Tetracycline phosphate complex and sodium novobiocin capsules. | |
| 21:6.0.1.1.11.0.1.293 | SECTION 520.2345g
| 520.2345g Tetracycline hydrochloride and sodium novobiocin tablets. | |
| 21:6.0.1.1.11.0.1.294 | SECTION 520.2345h
| 520.2345h Tetracycline hydrochloride, sodium novobiocin, and prednisolone tablets. | |
| 21:6.0.1.1.11.0.1.295 | SECTION 520.2362
| 520.2362 Thenium closylate. | |
| 21:6.0.1.1.11.0.1.296 | SECTION 520.2380
| 520.2380 Thiabendazole oral dosage forms. | |
| 21:6.0.1.1.11.0.1.297 | SECTION 520.2380a
| 520.2380a Thiabendazole top dressing and mineral protein block. | |
| 21:6.0.1.1.11.0.1.298 | SECTION 520.2380b
| 520.2380b Thiabendazole drench or paste. | |
| 21:6.0.1.1.11.0.1.299 | SECTION 520.2380c
| 520.2380c Thiabendazole bolus. | |
| 21:6.0.1.1.11.0.1.300 | SECTION 520.2380d
| 520.2380d Thiabendazole and piperazine citrate. | |
| 21:6.0.1.1.11.0.1.301 | SECTION 520.2380e
| 520.2380e Thiabendazole and piperazine phosphate. | |
| 21:6.0.1.1.11.0.1.302 | SECTION 520.2380f
| 520.2380f Thiabendazole and triclorfon. | |
| 21:6.0.1.1.11.0.1.303 | SECTION 520.2455
| 520.2455 Tiamulin. | |
| 21:6.0.1.1.11.0.1.304 | SECTION 520.2471
| 520.2471 Tilmicosin. | |
| 21:6.0.1.1.11.0.1.305 | SECTION 520.2473
| 520.2473 Tioxidazole oral dosage forms. | |
| 21:6.0.1.1.11.0.1.306 | SECTION 520.2473a
| 520.2473a Tioxidazole granules. | |
| 21:6.0.1.1.11.0.1.307 | SECTION 520.2473b
| 520.2473b Tioxidazole paste. | |
| 21:6.0.1.1.11.0.1.308 | SECTION 520.2475
| 520.2475 Toceranib. | |
| 21:6.0.1.1.11.0.1.309 | SECTION 520.2483
| 520.2483 Triamcinolone. | |
| 21:6.0.1.1.11.0.1.310 | SECTION 520.2520
| 520.2520 Trichlorfon oral dosage forms. | |
| 21:6.0.1.1.11.0.1.311 | SECTION 520.2520a
| 520.2520a Trichlorfon and atropine. | |
| 21:6.0.1.1.11.0.1.312 | SECTION 520.2520b
| 520.2520b Trichlorfon boluses. | |
| 21:6.0.1.1.11.0.1.313 | SECTION 520.2520c
| 520.2520c Trichlorfon granules. | |
| 21:6.0.1.1.11.0.1.314 | SECTION 520.2520d
| 520.2520d Trichlorfon, phenothiazine, and piperazine. | |
| 21:6.0.1.1.11.0.1.315 | SECTION 520.2582
| 520.2582 Triflupromazine. | |
| 21:6.0.1.1.11.0.1.316 | SECTION 520.2598
| 520.2598 Trilostane. | |
| 21:6.0.1.1.11.0.1.317 | SECTION 520.2604
| 520.2604 Trimeprazine and prednisolone tablets. | |
| 21:6.0.1.1.11.0.1.318 | SECTION 520.2605
| 520.2605 Trimeprazine and prednisolone capsules. | |
| 21:6.0.1.1.11.0.1.319 | SECTION 520.2610
| 520.2610 Trimethoprim and sulfadiazine tablets. | |
| 21:6.0.1.1.11.0.1.320 | SECTION 520.2611
| 520.2611 Trimethoprim and sulfadiazine paste. | |
| 21:6.0.1.1.11.0.1.321 | SECTION 520.2612
| 520.2612 Trimethoprim and sulfadiazine suspension. | |
| 21:6.0.1.1.11.0.1.322 | SECTION 520.2613
| 520.2613 Trimethoprim and sulfadiazine powder. | |
| 21:6.0.1.1.11.0.1.323 | SECTION 520.2640
| 520.2640 Tylosin. | |
| 21:6.0.1.1.11.0.1.324 | SECTION 520.2645
| 520.2645 Tylvalosin. | |
| 21:6.0.1.1.12 | PART 522
| PART 522 - IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS | |
| 21:6.0.1.1.12.0.1.1 | SECTION 522.23
| 522.23 Acepromazine. | |
| 21:6.0.1.1.12.0.1.2 | SECTION 522.52
| 522.52 Alfaxalone. | |
| 21:6.0.1.1.12.0.1.3 | SECTION 522.56
| 522.56 Amikacin. | |
| 21:6.0.1.1.12.0.1.4 | SECTION 522.62
| 522.62 Aminopentamide. | |
| 21:6.0.1.1.12.0.1.5 | SECTION 522.82
| 522.82 Aminopropazine. | |
| 21:6.0.1.1.12.0.1.6 | SECTION 522.88
| 522.88 Amoxicillin. | |
| 21:6.0.1.1.12.0.1.7 | SECTION 522.90
| 522.90 Ampicillin injectable dosage forms. | |
| 21:6.0.1.1.12.0.1.8 | SECTION 522.90a
| 522.90a Ampicillin trihydrate suspension. | |
| 21:6.0.1.1.12.0.1.9 | SECTION 522.90b
| 522.90b Ampicillin trihydrate powder for injection. | |
| 21:6.0.1.1.12.0.1.10 | SECTION 522.90c
| 522.90c Ampicillin sodium. | |
| 21:6.0.1.1.12.0.1.11 | SECTION 522.144
| 522.144 Arsenamide. | |
| 21:6.0.1.1.12.0.1.12 | SECTION 522.147
| 522.147 Atipamezole. | |
| 21:6.0.1.1.12.0.1.13 | SECTION 522.150
| 522.150 Azaperone. | |
| 21:6.0.1.1.12.0.1.14 | SECTION 522.161
| 522.161 Betamethasone. | |
| 21:6.0.1.1.12.0.1.15 | SECTION 522.163
| 522.163 Betamethasone dipropionate and betamethasone sodium phosphate aqueous suspension. | |
| 21:6.0.1.1.12.0.1.16 | SECTION 522.167
| 522.167 Betamethasone sodium phosphate and betamethasone acetate. | |
| 21:6.0.1.1.12.0.1.17 | SECTION 522.204
| 522.204 Boldenone. | |
| 21:6.0.1.1.12.0.1.18 | SECTION 522.224
| 522.224 Bupivacaine. | |
| 21:6.0.1.1.12.0.1.19 | SECTION 522.230
| 522.230 Buprenorphine. | |
| 21:6.0.1.1.12.0.1.20 | SECTION 522.234
| 522.234 Butamisole. | |
| 21:6.0.1.1.12.0.1.21 | SECTION 522.246
| 522.246 Butorphanol. | |
| 21:6.0.1.1.12.0.1.22 | SECTION 522.275
| 522.275 N-Butylscopolammonium. | |
| 21:6.0.1.1.12.0.1.23 | SECTION 522.304
| 522.304 Carprofen. | |
| 21:6.0.1.1.12.0.1.24 | SECTION 522.311
| 522.311 Cefovecin. | |
| 21:6.0.1.1.12.0.1.25 | SECTION 522.313
| 522.313 Ceftiofur injectable dosage forms. | |
| 21:6.0.1.1.12.0.1.26 | SECTION 522.313a
| 522.313a Ceftiofur crystalline free acid. | |
| 21:6.0.1.1.12.0.1.27 | SECTION 522.313b
| 522.313b Ceftiofur hydrochloride. | |
| 21:6.0.1.1.12.0.1.28 | SECTION 522.313c
| 522.313c Ceftiofur sodium. | |
| 21:6.0.1.1.12.0.1.29 | SECTION 522.380
| 522.380 Chloral hydrate, pentobarbital, and magnesium sulfate. | |
| 21:6.0.1.1.12.0.1.30 | SECTION 522.390
| 522.390 Chloramphenicol. | |
| 21:6.0.1.1.12.0.1.31 | SECTION 522.454
| 522.454 Clodronate. | |
| 21:6.0.1.1.12.0.1.32 | SECTION 522.460
| 522.460 Cloprostenol. | |
| 21:6.0.1.1.12.0.1.33 | SECTION 522.468
| 522.468 Colistimethate sodium powder for injection. | |
| 21:6.0.1.1.12.0.1.34 | SECTION 522.480
| 522.480 Corticotropin. | |
| 21:6.0.1.1.12.0.1.35 | SECTION 522.522
| 522.522 Danofloxacin. | |
| 21:6.0.1.1.12.0.1.36 | SECTION 522.533
| 522.533 Deslorelin. | |
| 21:6.0.1.1.12.0.1.37 | SECTION 522.535
| 522.535 Desoxycorticosterone. | |
| 21:6.0.1.1.12.0.1.38 | SECTION 522.536
| 522.536 Detomidine. | |
| 21:6.0.1.1.12.0.1.39 | SECTION 522.540
| 522.540 Dexamethasone solution. | |
| 21:6.0.1.1.12.0.1.40 | SECTION 522.542
| 522.542 Dexamethasone suspension. | |
| 21:6.0.1.1.12.0.1.41 | SECTION 522.558
| 522.558 Dexmedetomidine. | |
| 21:6.0.1.1.12.0.1.42 | SECTION 522.563
| 522.563 Diatrizoate. | |
| 21:6.0.1.1.12.0.1.43 | SECTION 522.650
| 522.650 Dihydrostreptomycin sulfate injection. | |
| 21:6.0.1.1.12.0.1.44 | SECTION 522.690
| 522.690 Dinoprost. | |
| 21:6.0.1.1.12.0.1.45 | SECTION 522.723
| 522.723 Diprenorphine. | |
| 21:6.0.1.1.12.0.1.46 | SECTION 522.728
| 522.728 Dipyrone. | |
| 21:6.0.1.1.12.0.1.47 | SECTION 522.770
| 522.770 Doramectin. | |
| 21:6.0.1.1.12.0.1.48 | SECTION 522.775
| 522.775 Doxapram. | |
| 21:6.0.1.1.12.0.1.49 | SECTION 522.784
| 522.784 Doxylamine. | |
| 21:6.0.1.1.12.0.1.50 | SECTION 522.800
| 522.800 Droperidol and fentanyl. | |
| 21:6.0.1.1.12.0.1.51 | SECTION 522.810
| 522.810 Embutramide, chloroquine, and lidocaine solution. | |
| 21:6.0.1.1.12.0.1.52 | SECTION 522.812
| 522.812 Enrofloxacin. | |
| 21:6.0.1.1.12.0.1.53 | SECTION 522.814
| 522.814 Eprinomectin. | |
| 21:6.0.1.1.12.0.1.54 | SECTION 522.820
| 522.820 Erythromycin. | |
| 21:6.0.1.1.12.0.1.55 | SECTION 522.840
| 522.840 Estradiol. | |
| 21:6.0.1.1.12.0.1.56 | SECTION 522.842
| 522.842 Estradiol benzoate and testosterone propionate. | |
| 21:6.0.1.1.12.0.1.57 | SECTION 522.850
| 522.850 Estradiol valerate and norgestomet in combination. | |
| 21:6.0.1.1.12.0.1.58 | SECTION 522.863
| 522.863 Ethylisobutrazine. | |
| 21:6.0.1.1.12.0.1.59 | SECTION 522.870
| 522.870 Etodolac. | |
| 21:6.0.1.1.12.0.1.60 | SECTION 522.883
| 522.883 Etorphine. | |
| 21:6.0.1.1.12.0.1.61 | SECTION 522.914
| 522.914 Fenprostalene. | |
| 21:6.0.1.1.12.0.1.62 | SECTION 522.930
| 522.930 Firocoxib. | |
| 21:6.0.1.1.12.0.1.63 | SECTION 522.955
| 522.955 Florfenicol. | |
| 21:6.0.1.1.12.0.1.64 | SECTION 522.956
| 522.956 Florfenicol and flunixin. | |
| 21:6.0.1.1.12.0.1.65 | SECTION 522.960
| 522.960 Flumethasone injectable dosage forms. | |
| 21:6.0.1.1.12.0.1.66 | SECTION 522.960a
| 522.960a Flumethasone suspension. | |
| 21:6.0.1.1.12.0.1.67 | SECTION 522.960b
| 522.960b Flumethasone acetate solution. | |
| 21:6.0.1.1.12.0.1.68 | SECTION 522.960c
| 522.960c Flumethasone solution. | |
| 21:6.0.1.1.12.0.1.69 | SECTION 522.970
| 522.970 Flunixin. | |
| 21:6.0.1.1.12.0.1.70 | SECTION 522.995
| 522.995 Fluprostenol. | |
| 21:6.0.1.1.12.0.1.71 | SECTION 522.1002
| 522.1002 Follicle stimulating hormone. | |
| 21:6.0.1.1.12.0.1.72 | SECTION 522.1010
| 522.1010 Furosemide. | |
| 21:6.0.1.1.12.0.1.73 | SECTION 522.1014
| 522.1014 Gamithromycin. | |
| 21:6.0.1.1.12.0.1.74 | SECTION 522.1020
| 522.1020 Gelatin. | |
| 21:6.0.1.1.12.0.1.75 | SECTION 522.1044
| 522.1044 Gentamicin. | |
| 21:6.0.1.1.12.0.1.76 | SECTION 522.1055
| 522.1055 Gleptoferron. | |
| 21:6.0.1.1.12.0.1.77 | SECTION 522.1066
| 522.1066 Glycopyrrolate. | |
| 21:6.0.1.1.12.0.1.78 | SECTION 522.1077
| 522.1077 Gonadorelin. | |
| 21:6.0.1.1.12.0.1.79 | SECTION 522.1079
| 522.1079 Serum gonadotropin and chorionic gonadotropin. | |
| 21:6.0.1.1.12.0.1.80 | SECTION 522.1081
| 522.1081 Chorionic gonadotropin. | |
| 21:6.0.1.1.12.0.1.81 | SECTION 522.1083
| 522.1083 Gonadotropin releasing factor analog-diphtheria toxoid conjugate. | |
| 21:6.0.1.1.12.0.1.82 | SECTION 522.1085
| 522.1085 Guaifenesin powder for injection. | |
| 21:6.0.1.1.12.0.1.83 | SECTION 522.1086
| 522.1086 Guaifenesin solution. | |
| 21:6.0.1.1.12.0.1.84 | SECTION 522.1125
| 522.1125 Hemoglobin glutamer-200 (bovine). | |
| 21:6.0.1.1.12.0.1.85 | SECTION 522.1145
| 522.1145 Hyaluronate. | |
| 21:6.0.1.1.12.0.1.86 | SECTION 522.1150
| 522.1150 Hydrochlorothiazide. | |
| 21:6.0.1.1.12.0.1.87 | SECTION 522.1155
| 522.1155 Imidocarb powder for injection. | |
| 21:6.0.1.1.12.0.1.88 | SECTION 522.1156
| 522.1156 Imidocarb solution. | |
| 21:6.0.1.1.12.0.1.89 | SECTION 522.1160
| 522.1160 Insulin. | |
| 21:6.0.1.1.12.0.1.90 | SECTION 522.1182
| 522.1182 Iron injection. | |
| 21:6.0.1.1.12.0.1.91 | SECTION 522.1185
| 522.1185 Isoflupredone. | |
| 21:6.0.1.1.12.0.1.92 | SECTION 522.1192
| 522.1192 Ivermectin. | |
| 21:6.0.1.1.12.0.1.93 | SECTION 522.1193
| 522.1193 Ivermectin and clorsulon. | |
| 21:6.0.1.1.12.0.1.94 | SECTION 522.1204
| 522.1204 Kanamycin. | |
| 21:6.0.1.1.12.0.1.95 | SECTION 522.1222
| 522.1222 Ketamine. | |
| 21:6.0.1.1.12.0.1.96 | SECTION 522.1223
| 522.1223 Ketamine, promazine, and aminopentamide. | |
| 21:6.0.1.1.12.0.1.97 | SECTION 522.1225
| 522.1225 Ketoprofen. | |
| 21:6.0.1.1.12.0.1.98 | SECTION 522.1242
| 522.1242 Levamisole. | |
| 21:6.0.1.1.12.0.1.99 | SECTION 522.1260
| 522.1260 Lincomycin. | |
| 21:6.0.1.1.12.0.1.100 | SECTION 522.1289
| 522.1289 Lufenuron. | |
| 21:6.0.1.1.12.0.1.101 | SECTION 522.1290
| 522.1290 Luprostiol. | |
| 21:6.0.1.1.12.0.1.102 | SECTION 522.1315
| 522.1315 Maropitant. | |
| 21:6.0.1.1.12.0.1.103 | SECTION 522.1335
| 522.1335 Medetomidine. | |
| 21:6.0.1.1.12.0.1.104 | SECTION 522.1350
| 522.1350 Melatonin implant. | |
| 21:6.0.1.1.12.0.1.105 | SECTION 522.1362
| 522.1362 Melarsomine powder for injection. | |
| 21:6.0.1.1.12.0.1.106 | SECTION 522.1367
| 522.1367 Meloxicam. | |
| 21:6.0.1.1.12.0.1.107 | SECTION 522.1372
| 522.1372 Mepivacaine. | |
| 21:6.0.1.1.12.0.1.108 | SECTION 522.1380
| 522.1380 Methocarbamol. | |
| 21:6.0.1.1.12.0.1.109 | SECTION 522.1410
| 522.1410 Methylprednisolone. | |
| 21:6.0.1.1.12.0.1.110 | SECTION 522.1450
| 522.1450 Moxidectin solution. | |
| 21:6.0.1.1.12.0.1.111 | SECTION 522.1451
| 522.1451 Moxidectin microspheres for injection. | |
| 21:6.0.1.1.12.0.1.112 | SECTION 522.1452
| 522.1452 Nalorphine. | |
| 21:6.0.1.1.12.0.1.113 | SECTION 522.1465
| 522.1465 Naltrexone. | |
| 21:6.0.1.1.12.0.1.114 | SECTION 522.1468
| 522.1468 Naproxen for injection. | |
| 21:6.0.1.1.12.0.1.115 | SECTION 522.1484
| 522.1484 Neomycin. | |
| 21:6.0.1.1.12.0.1.116 | SECTION 522.1503
| 522.1503 Neostigmine. | |
| 21:6.0.1.1.12.0.1.117 | SECTION 522.1610
| 522.1610 Oleate sodium. | |
| 21:6.0.1.1.12.0.1.118 | SECTION 522.1660
| 522.1660 Oxytetracycline injectable dosage forms. | |
| 21:6.0.1.1.12.0.1.119 | SECTION 522.1660a
| 522.1660a Oxytetracycline solution, 200 milligrams/milliliter. | |
| 21:6.0.1.1.12.0.1.120 | SECTION 522.1660b
| 522.1660b Oxytetracycline solution, 300 milligrams/milliliter. | |
| 21:6.0.1.1.12.0.1.121 | SECTION 522.1662
| 522.1662 Oxytetracycline hydrochloride implantation or injectable dosage forms. | |
| 21:6.0.1.1.12.0.1.122 | SECTION 522.1662a
| 522.1662a Oxytetracycline hydrochloride injection. | |
| 21:6.0.1.1.12.0.1.123 | SECTION 522.1662b
| 522.1662b Oxytetracycline hydrochloride with lidocaine injection. | |
| 21:6.0.1.1.12.0.1.124 | SECTION 522.1664
| 522.1664 Oxytetracycline and flunixin. | |
| 21:6.0.1.1.12.0.1.125 | SECTION 522.1680
| 522.1680 Oxytocin. | |
| 21:6.0.1.1.12.0.1.126 | SECTION 522.1684
| 522.1684 Pegbovigrastim. | |
| 21:6.0.1.1.12.0.1.127 | SECTION 522.1696
| 522.1696 Penicillin G procaine injectable dosage forms. | |
| 21:6.0.1.1.12.0.1.128 | SECTION 522.1696a
| 522.1696a Penicillin G benzathine and penicillin G procaine suspension. | |
| 21:6.0.1.1.12.0.1.129 | SECTION 522.1696b
| 522.1696b Penicillin G procaine aqueous suspension. | |
| 21:6.0.1.1.12.0.1.130 | SECTION 522.1696c
| 522.1696c Penicillin G procaine in oil. | |
| 21:6.0.1.1.12.0.1.131 | SECTION 522.1697
| 522.1697 Pentobarbital and phenytoin. | |
| 21:6.0.1.1.12.0.1.132 | SECTION 522.1698
| 522.1698 Pentazocine. | |
| 21:6.0.1.1.12.0.1.133 | SECTION 522.1704
| 522.1704 Pentobarbital. | |
| 21:6.0.1.1.12.0.1.134 | SECTION 522.1720
| 522.1720 Phenylbutazone. | |
| 21:6.0.1.1.12.0.1.135 | SECTION 522.1820
| 522.1820 Pituitary luteinizing hormone powder for injection. | |
| 21:6.0.1.1.12.0.1.136 | SECTION 522.1850
| 522.1850 Polysulfated glycosaminoglycan. | |
| 21:6.0.1.1.12.0.1.137 | SECTION 522.1862
| 522.1862 Pralidoxime powder for injection. | |
| 21:6.0.1.1.12.0.1.138 | SECTION 522.1870
| 522.1870 Praziquantel. | |
| 21:6.0.1.1.12.0.1.139 | SECTION 522.1881
| 522.1881 Prednisolone acetate. | |
| 21:6.0.1.1.12.0.1.140 | SECTION 522.1883
| 522.1883 Prednisolone sodium phosphate. | |
| 21:6.0.1.1.12.0.1.141 | SECTION 522.1884
| 522.1884 Prednisolone sodium succinate. | |
| 21:6.0.1.1.12.0.1.142 | SECTION 522.1885
| 522.1885 Prednisolone tertiary butylacetate. | |
| 21:6.0.1.1.12.0.1.143 | SECTION 522.1890
| 522.1890 Sterile prednisone suspension. | |
| 21:6.0.1.1.12.0.1.144 | SECTION 522.1920
| 522.1920 Prochlorperazine and isopropamide. | |
| 21:6.0.1.1.12.0.1.145 | SECTION 522.1940
| 522.1940 Progesterone and estradiol benzoate. | |
| 21:6.0.1.1.12.0.1.146 | SECTION 522.1962
| 522.1962 Promazine. | |
| 21:6.0.1.1.12.0.1.147 | SECTION 522.2002
| 522.2002 Propiopromazine. | |
| 21:6.0.1.1.12.0.1.148 | SECTION 522.2005
| 522.2005 Propofol. | |
| 21:6.0.1.1.12.0.1.149 | SECTION 522.2012
| 522.2012 Prostalene. | |
| 21:6.0.1.1.12.0.1.150 | SECTION 522.2063
| 522.2063 Pyrilamine. | |
| 21:6.0.1.1.12.0.1.151 | SECTION 522.2075
| 522.2075 Robenacoxib. | |
| 21:6.0.1.1.12.0.1.152 | SECTION 522.2076
| 522.2076 Romifidine. | |
| 21:6.0.1.1.12.0.1.153 | SECTION 522.2092
| 522.2092 Secobarbital and dibucaine. | |
| 21:6.0.1.1.12.0.1.154 | SECTION 522.2100
| 522.2100 Selenium and vitamin E. | |
| 21:6.0.1.1.12.0.1.155 | SECTION 522.2112
| 522.2112 Sometribove zinc suspension. | |
| 21:6.0.1.1.12.0.1.156 | SECTION 522.2120
| 522.2120 Spectinomycin dihydrochloride injection. | |
| 21:6.0.1.1.12.0.1.157 | SECTION 522.2121
| 522.2121 Spectinomycin sulfate. | |
| 21:6.0.1.1.12.0.1.158 | SECTION 522.2150
| 522.2150 Stanozolol. | |
| 21:6.0.1.1.12.0.1.159 | SECTION 522.2200
| 522.2200 Sulfachlorpyridazine. | |
| 21:6.0.1.1.12.0.1.160 | SECTION 522.2220
| 522.2220 Sulfadimethoxine. | |
| 21:6.0.1.1.12.0.1.161 | SECTION 522.2240
| 522.2240 Sulfaethoxypyridazine. | |
| 21:6.0.1.1.12.0.1.162 | SECTION 522.2260
| 522.2260 Sulfamethazine. | |
| 21:6.0.1.1.12.0.1.163 | SECTION 522.2340
| 522.2340 Sulfomyxin. | |
| 21:6.0.1.1.12.0.1.164 | SECTION 522.2404
| 522.2404 Thialbarbitone sodium for injection. | |
| 21:6.0.1.1.12.0.1.165 | SECTION 522.2424
| 522.2424 Thiamylal. | |
| 21:6.0.1.1.12.0.1.166 | SECTION 522.2444
| 522.2444 Thiopental injectable dosage forms. | |
| 21:6.0.1.1.12.0.1.167 | SECTION 522.2444a
| 522.2444a Thiopental powder for injection. | |
| 21:6.0.1.1.12.0.1.168 | SECTION 522.2444b
| 522.2444b Thiopental and pentobarbital powder for injection. | |
| 21:6.0.1.1.12.0.1.169 | SECTION 522.2460
| 522.2460 Tildipirosin. | |
| 21:6.0.1.1.12.0.1.170 | SECTION 522.2470
| 522.2470 Tiletamine and zolazepam for injection. | |
| 21:6.0.1.1.12.0.1.171 | SECTION 522.2471
| 522.2471 Tilmicosin. | |
| 21:6.0.1.1.12.0.1.172 | SECTION 522.2473
| 522.2473 Tiludronate. | |
| 21:6.0.1.1.12.0.1.173 | SECTION 522.2474
| 522.2474 Tolazoline. | |
| 21:6.0.1.1.12.0.1.174 | SECTION 522.2476
| 522.2476 Trenbolone acetate. | |
| 21:6.0.1.1.12.0.1.175 | SECTION 522.2477
| 522.2477 Trenbolone acetate and estradiol. | |
| 21:6.0.1.1.12.0.1.176 | SECTION 522.2478
| 522.2478 Trenbolone acetate and estradiol benzoate. | |
| 21:6.0.1.1.12.0.1.177 | SECTION 522.2483
| 522.2483 Triamcinolone. | |
| 21:6.0.1.1.12.0.1.178 | SECTION 522.2582
| 522.2582 Triflupromazine. | |
| 21:6.0.1.1.12.0.1.179 | SECTION 522.2610
| 522.2610 Trimethoprim and sulfadiazine. | |
| 21:6.0.1.1.12.0.1.180 | SECTION 522.2615
| 522.2615 Tripelennamine. | |
| 21:6.0.1.1.12.0.1.181 | SECTION 522.2630
| 522.2630 Tulathromycin. | |
| 21:6.0.1.1.12.0.1.182 | SECTION 522.2640
| 522.2640 Tylosin. | |
| 21:6.0.1.1.12.0.1.183 | SECTION 522.2662
| 522.2662 Xylazine. | |
| 21:6.0.1.1.12.0.1.184 | SECTION 522.2670
| 522.2670 Yohimbine. | |
| 21:6.0.1.1.12.0.1.185 | SECTION 522.2680
| 522.2680 Zeranol. | |
| 21:6.0.1.1.12.0.1.186 | SECTION 522.2690
| 522.2690 Zinc gluconate. | |
| 21:6.0.1.1.13 | PART 524
| PART 524 - OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS | |
| 21:6.0.1.1.13.0.1 | SUBJGRP 1
| Fluocinolone Topical and Otic Dosage Forms | |
| 21:6.0.1.1.13.0.1.1 | SECTION 524.86
| 524.86 Amitraz. | |
| 21:6.0.1.1.13.0.1.2 | SECTION 524.154
| 524.154 Bacitracin, neomycin, and polymyxin B ophthalmic ointment. | |
| 21:6.0.1.1.13.0.1.3 | SECTION 524.155
| 524.155 Bacitracin, neomycin, polymyxin B, and hydrocortisone ophthalmic ointment. | |
| 21:6.0.1.1.13.0.1.4 | SECTION 524.390
| 524.390 Chloramphenicol ophthalmic ointment. | |
| 21:6.0.1.1.13.0.1.5 | SECTION 524.402
| 524.402 Chlorhexidine. | |
| 21:6.0.1.1.13.0.1.6 | SECTION 524.450
| 524.450 Clotrimazole. | |
| 21:6.0.1.1.13.0.1.7 | SECTION 524.463
| 524.463 Copper naphthenate. | |
| 21:6.0.1.1.13.0.1.8 | SECTION 524.575
| 524.575 Cyclosporine ophthalmic ointment. | |
| 21:6.0.1.1.13.0.1.9 | SECTION 524.590
| 524.590 Diclofenac. | |
| 21:6.0.1.1.13.0.1.10 | SECTION 524.660
| 524.660 Dimethyl sulfoxide. | |
| 21:6.0.1.1.13.0.1.11 | SECTION 524.770
| 524.770 Doramectin. | |
| 21:6.0.1.1.13.0.1.12 | SECTION 524.775
| 524.775 Emodepside and praziquantel. | |
| 21:6.0.1.1.13.0.1.13 | SECTION 524.802
| 524.802 Enrofloxacin and silver sulfadiazine otic emulsion. | |
| 21:6.0.1.1.13.0.1.14 | SECTION 524.814
| 524.814 Eprinomectin. | |
| 21:6.0.1.1.13.0.1.15 | SECTION 524.815
| 524.815 Eprinomectin and praziquantel. | |
| 21:6.0.1.1.13.0.1.16 | SECTION 524.900
| 524.900 Famphur. | |
| 21:6.0.1.1.13.0.1.17 | SECTION 524.920
| 524.920 Fenthion. | |
| 21:6.0.1.1.13.0.1.18 | SECTION 524.955
| 524.955 Florfenicol, terbinafine, and betamethasone acetate otic gel. | |
| 21:6.0.1.1.13.0.1.19 | SECTION 524.957
| 524.957 Florfenicol, terbinafine, and mometasone otic solution. | |
| 21:6.0.1.1.13.0.1.20 | SECTION 524.960
| 524.960 Flumethasone, neomycin, and polymyxin B ophthalmic solution. | |
| 21:6.0.1.1.13.0.1.21 | SECTION 524.970
| 524.970 Flunixin. | |
| 21:6.0.1.1.13.0.1.22 | SECTION 524.981
| 524.981 [Reserved] | |
| 21:6.0.1.1.13.0.1.23 | SECTION 524.981a
| 524.981a Fluocinolone cream. | |
| 21:6.0.1.1.13.0.1.24 | SECTION 524.981b
| 524.981b Fluocinolone solution. | |
| 21:6.0.1.1.13.0.1.25 | SECTION 524.981c
| 524.981c Fluocinolone and neomycin cream. | |
| 21:6.0.1.1.13.0.1.26 | SECTION 524.981d
| 524.981d Fluocinolone and dimethyl sulfoxide solution. | |
| 21:6.0.1.1.13.0.1.27 | SECTION 524.981e
| 524.981e Fluocinolone and dimethyl sulfoxide otic solution. | |
| 21:6.0.1.1.13.0.1.28 | SECTION 524.998
| 524.998 Fluralaner. | |
| 21:6.0.1.1.13.0.1.29 | SECTION 524.1001
| 524.1001 Furalaner and moxidectin. | |
| 21:6.0.1.1.13.0.1.30 | SECTION 524.1005
| 524.1005 Furazolidone powder. | |
| 21:6.0.1.1.13.0.1.31 | SECTION 524.1044
| 524.1044 Gentamicin ophthalmic and topical dosage forms. | |
| 21:6.0.1.1.13.0.1.32 | SECTION 524.1044a
| 524.1044a Gentamicin ophthalmic solution. | |
| 21:6.0.1.1.13.0.1.33 | SECTION 524.1044b
| 524.1044b Gentamicin and betamethasone otic solution. | |
| 21:6.0.1.1.13.0.1.34 | SECTION 524.1044c
| 524.1044c Gentamicin ophthalmic ointment. | |
| 21:6.0.1.1.13.0.1.35 | SECTION 524.1044d
| 524.1044d Gentamicin and betamethasone ointment. | |
| 21:6.0.1.1.13.0.1.36 | SECTION 524.1044e
| 524.1044e Gentamicin spray. | |
| 21:6.0.1.1.13.0.1.37 | SECTION 524.1044f
| 524.1044f Gentamicin and betamethasone spray. | |
| 21:6.0.1.1.13.0.1.38 | SECTION 524.1044g
| 524.1044g Gentamicin, betamethasone, and clotrimazole ointment. | |
| 21:6.0.1.1.13.0.1.39 | SECTION 524.1044h
| 524.1044h Gentamicin, mometasone, and clotrimazole otic suspension. | |
| 21:6.0.1.1.13.0.1.40 | SECTION 524.1044i
| 524.1044i Gentamicin and betamethasone ophthalmic solution. | |
| 21:6.0.1.1.13.0.1.41 | SECTION 524.1132
| 524.1132 Hydrocortisone, miconazole, and gentamicin otic suspension. | |
| 21:6.0.1.1.13.0.1.42 | SECTION 524.1140
| 524.1140 Imidacloprid and ivermectin. | |
| 21:6.0.1.1.13.0.1.43 | SECTION 524.1146
| 524.1146 Imidacloprid and moxidectin. | |
| 21:6.0.1.1.13.0.1.44 | SECTION 524.1193
| 524.1193 Ivermectin topical solution. | |
| 21:6.0.1.1.13.0.1.45 | SECTION 524.1195
| 524.1195 Ivermectin otic suspension. | |
| 21:6.0.1.1.13.0.1.46 | SECTION 524.1200
| 524.1200 Kanamycin ophthalmic and topical dosage forms. | |
| 21:6.0.1.1.13.0.1.47 | SECTION 524.1200a
| 524.1200a Kanamycin ophthalmic ointment. | |
| 21:6.0.1.1.13.0.1.48 | SECTION 524.1200b
| 524.1200b Kanamycin ophthalmic solution. | |
| 21:6.0.1.1.13.0.1.49 | SECTION 524.1204
| 524.1204 Kanamycin, amphomycin, and hydrocortisone ointment. | |
| 21:6.0.1.1.13.0.1.50 | SECTION 524.1240
| 524.1240 Levamisole. | |
| 21:6.0.1.1.13.0.1.51 | SECTION 524.1376
| 524.1376 2-Mercaptobenzothiazole solution. | |
| 21:6.0.1.1.13.0.1.52 | SECTION 524.1443
| 524.1443 Miconazole. | |
| 21:6.0.1.1.13.0.1.53 | SECTION 524.1445
| 524.1445 Miconazole, polymixin B, and prednisolone suspension. | |
| 21:6.0.1.1.13.0.1.54 | SECTION 524.1446
| 524.1446 Milbemycin otic solution. | |
| 21:6.0.1.1.13.0.1.55 | SECTION 524.1448
| 524.1448 Mirtazapine transdermal ointment. | |
| 21:6.0.1.1.13.0.1.56 | SECTION 524.1450
| 524.1450 Moxidectin. | |
| 21:6.0.1.1.13.0.1.57 | SECTION 524.1465
| 524.1465 Mupirocin. | |
| 21:6.0.1.1.13.0.1.58 | SECTION 524.1484
| 524.1484 Neomycin ophthalmic and topical dosage forms. | |
| 21:6.0.1.1.13.0.1.59 | SECTION 524.1484b
| 524.1484b Neomycin, isoflupredone, and tetracaine powder. | |
| 21:6.0.1.1.13.0.1.60 | SECTION 524.1484c
| 524.1484c Neomycin, isoflupredone, and tetracaine ointment. | |
| 21:6.0.1.1.13.0.1.61 | SECTION 524.1484d
| 524.1484d Neomycin, hydrocortisone, and tetracaine otic ointment. | |
| 21:6.0.1.1.13.0.1.62 | SECTION 524.1484e
| 524.1484e Neomycin and polymyxin B ophthalmic solution. | |
| 21:6.0.1.1.13.0.1.63 | SECTION 524.1484f
| 524.1484f Neomycin, prednisolone, and tetracaine otic suspension. | |
| 21:6.0.1.1.13.0.1.64 | SECTION 524.1484g
| 524.1484g Neomycin, thiabendazole, and dexamethasone solution. | |
| 21:6.0.1.1.13.0.1.65 | SECTION 524.1484h
| 524.1484h Neomycin, penicillin, polymyxin B, and hydrocortisone suspension. | |
| 21:6.0.1.1.13.0.1.66 | SECTION 524.1484i
| 524.1484i Neomycin and hydrocortisone ointment. | |
| 21:6.0.1.1.13.0.1.67 | SECTION 524.1484j
| 524.1484j Neomycin and prednisolone ophthalmic ointment. | |
| 21:6.0.1.1.13.0.1.68 | SECTION 524.1484k
| 524.1484k Neomycin and prednisolone suspension. | |
| 21:6.0.1.1.13.0.1.69 | SECTION 524.1580
| 524.1580 Nitrofurazone topical dosage forms. | |
| 21:6.0.1.1.13.0.1.70 | SECTION 524.1580a
| 524.1580a Nitrofurazone ointment. | |
| 21:6.0.1.1.13.0.1.71 | SECTION 524.1580b
| 524.1580b Nitrofurazone soluble powder. | |
| 21:6.0.1.1.13.0.1.72 | SECTION 524.1580c
| 524.1580c Nitrofurazone and butacaine ointment. | |
| 21:6.0.1.1.13.0.1.73 | SECTION 524.1600
| 524.1600 Nystatin ophthalmic and topical dosage forms. | |
| 21:6.0.1.1.13.0.1.74 | SECTION 524.1600a
| 524.1600a Nystatin, neomycin, thiostrepton, and triamcinolone ointment. | |
| 21:6.0.1.1.13.0.1.75 | SECTION 524.1600b
| 524.1600b Nystatin, neomycin, thiostrepton, and triamcinolone ophthalmic ointment. | |
| 21:6.0.1.1.13.0.1.76 | SECTION 524.1610
| 524.1610 Orbifloxacin, mometasone furoate monohydrate, and posaconazole suspension. | |
| 21:6.0.1.1.13.0.1.77 | SECTION 524.1662
| 524.1662 Oxytetracycline ophthalmic and topical dosage forms. | |
| 21:6.0.1.1.13.0.1.78 | SECTION 524.1662a
| 524.1662a Oxytetracycline and hydrocortisone spray. | |
| 21:6.0.1.1.13.0.1.79 | SECTION 524.1662b
| 524.1662b Oxytetracycline and polymyxin B ophthalmic ointment. | |
| 21:6.0.1.1.13.0.1.80 | SECTION 524.1742
| 524.1742 Phosmet emulsifiable liquid. | |
| 21:6.0.1.1.13.0.1.81 | SECTION 524.1982
| 524.1982 Proparacaine ophthalmic solution. | |
| 21:6.0.1.1.13.0.1.82 | SECTION 524.2098
| 524.2098 Selamectin. | |
| 21:6.0.1.1.13.0.1.83 | SECTION 524.2099
| 524.2099 Selamectin and sarolaner. | |
| 21:6.0.1.1.13.0.1.84 | SECTION 524.2101
| 524.2101 Selenium disulfide suspension. | |
| 21:6.0.1.1.13.0.1.85 | SECTION 524.2350
| 524.2350 Tolnaftate cream. | |
| 21:6.0.1.1.13.0.1.86 | SECTION 524.2482
| 524.2482 Triamcinolone spray. | |
| 21:6.0.1.1.13.0.1.87 | SECTION 524.2483
| 524.2483 Triamcinolone cream. | |
| 21:6.0.1.1.13.0.1.88 | SECTION 524.2620
| 524.2620 Liquid crystalline trypsin, Peru balsam, castor oil. | |
| 21:6.0.1.1.14 | PART 526
| PART 526 - INTRAMAMMARY DOSAGE FORM NEW ANIMAL DRUGS | |
| 21:6.0.1.1.14.0.2.1 | SECTION 526.88
| 526.88 Amoxicillin trihydrate for intramammary infusion. | |
| 21:6.0.1.1.14.0.2.2 | SECTION 526.313
| 526.313 Ceftiofur. | |
| 21:6.0.1.1.14.0.2.3 | SECTION 526.363
| 526.363 Cephapirin benzathine. | |
| 21:6.0.1.1.14.0.2.4 | SECTION 526.365
| 526.365 Cephapirin sodium. | |
| 21:6.0.1.1.14.0.2.5 | SECTION 526.464
| 526.464 Cloxacillin intramammary dosage forms. | |
| 21:6.0.1.1.14.0.2.6 | SECTION 526.464a
| 526.464a Cloxacillin benzathine. | |
| 21:6.0.1.1.14.0.2.7 | SECTION 526.464b
| 526.464b Cloxacillin sodium for intramammary infusion, sterile. | |
| 21:6.0.1.1.14.0.2.8 | SECTION 526.820
| 526.820 Erythromycin. | |
| 21:6.0.1.1.14.0.2.9 | SECTION 526.1130
| 526.1130 Hetacillin. | |
| 21:6.0.1.1.14.0.2.10 | SECTION 526.1590
| 526.1590 Novobiocin infusion. | |
| 21:6.0.1.1.14.0.2.11 | SECTION 526.1696
| 526.1696 Penicillin intramammary dosage forms. | |
| 21:6.0.1.1.14.0.2.12 | SECTION 526.1696a
| 526.1696a Penicillin G procaine. | |
| 21:6.0.1.1.14.0.2.13 | SECTION 526.1696b
| 526.1696b Penicillin G procaine-dihydrostreptomycin in soybean oil for intramammary infusion (dry cows). | |
| 21:6.0.1.1.14.0.2.14 | SECTION 526.1696c
| 526.1696c Penicillin G procaine-dihydrostreptomycin sulfate for intramammary infusion (dry cows). | |
| 21:6.0.1.1.14.0.2.15 | SECTION 526.1696d
| 526.1696d Penicillin G procaine-novobiocin for intramammary infusion. | |
| 21:6.0.1.1.14.0.2.16 | SECTION 526.1810
| 526.1810 Pirlimycin. | |
| 21:6.0.1.1.15 | PART 528
| PART 528 - NEW ANIMAL DRUGS IN GENETICALLY ENGINEERED ANIMALS | |
| 21:6.0.1.1.15.0.2.1 | SECTION 528.1070
| 528.1070 Bc6 recombinant deoxyribonucleic acid construct. | |
| 21:6.0.1.1.15.0.2.2 | SECTION 528.1080
| 528.1080 Bc2371 recombinant deoxyribonucleic acid construct. | |
| 21:6.0.1.1.15.0.2.3 | SECTION 528.1092
| 528.1092 opAFP-GHc2 recombinant deoxyribonucleic acid construct. | |
| 21:6.0.1.1.15.0.2.4 | SECTION 528.2010
| 528.2010 Human lysosomal acid lipase recombinant deoxyribonucleic acid construct. | |
| 21:6.0.1.1.16 | PART 529
| PART 529 - CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS | |
| 21:6.0.1.1.16.0.2.1 | SECTION 529.40
| 529.40 Albuterol. | |
| 21:6.0.1.1.16.0.2.2 | SECTION 529.56
| 529.56 Amikacin. | |
| 21:6.0.1.1.16.0.2.3 | SECTION 529.382
| 529.382 Chloramine-T. | |
| 21:6.0.1.1.16.0.2.4 | SECTION 529.400
| 529.400 Chlorhexidine tablets and suspension. | |
| 21:6.0.1.1.16.0.2.5 | SECTION 529.536
| 529.536 Detomidine. | |
| 21:6.0.1.1.16.0.2.6 | SECTION 529.539
| 529.539 Dexmedetomidine. | |
| 21:6.0.1.1.16.0.2.7 | SECTION 529.778
| 529.778 Doxycycline. | |
| 21:6.0.1.1.16.0.2.8 | SECTION 529.1030
| 529.1030 Formalin. | |
| 21:6.0.1.1.16.0.2.9 | SECTION 529.1044
| 529.1044 Gentamicin in certain other dosage forms. | |
| 21:6.0.1.1.16.0.2.10 | SECTION 529.1044a
| 529.1044a Gentamicin solution for infusion. | |
| 21:6.0.1.1.16.0.2.11 | SECTION 529.1044b
| 529.1044b Gentamicin solution for dipping eggs. | |
| 21:6.0.1.1.16.0.2.12 | SECTION 529.1115
| 529.1115 Halothane. | |
| 21:6.0.1.1.16.0.2.13 | SECTION 529.1150
| 529.1150 Hydrogen peroxide. | |
| 21:6.0.1.1.16.0.2.14 | SECTION 529.1186
| 529.1186 Isoflurane. | |
| 21:6.0.1.1.16.0.2.15 | SECTION 529.1350
| 529.1350 Meloxicam. | |
| 21:6.0.1.1.16.0.2.16 | SECTION 529.1660
| 529.1660 Oxytetracycline. | |
| 21:6.0.1.1.16.0.2.17 | SECTION 529.1940
| 529.1940 Progesterone intravaginal inserts. | |
| 21:6.0.1.1.16.0.2.18 | SECTION 529.2150
| 529.2150 Sevoflurane. | |
| 21:6.0.1.1.16.0.2.19 | SECTION 529.2464
| 529.2464 Ticarcillin. | |
| 21:6.0.1.1.16.0.2.20 | SECTION 529.2503
| 529.2503 Tricaine methanesulfonate. | |
| 21:6.0.1.1.16.0.2.21 | SECTION 529.2620
| 529.2620 Triptorelin. | |
| 21:6.0.1.1.17 | PART 530
| PART 530 - EXTRALABEL DRUG USE IN ANIMALS | |
| 21:6.0.1.1.17.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.17.1.2.1 | SECTION 530.1
| 530.1 Scope. | |
| 21:6.0.1.1.17.1.2.2 | SECTION 530.2
| 530.2 Purpose. | |
| 21:6.0.1.1.17.1.2.3 | SECTION 530.3
| 530.3 Definitions. | |
| 21:6.0.1.1.17.1.2.4 | SECTION 530.4
| 530.4 Advertising and promotion. | |
| 21:6.0.1.1.17.1.2.5 | SECTION 530.5
| 530.5 Veterinary records. | |
| 21:6.0.1.1.17.2 | SUBPART B
| Subpart B - Rules and Provisions for Extralabel Uses of Drugs in Animals | |
| 21:6.0.1.1.17.2.2.1 | SECTION 530.10
| 530.10 Provision permitting extralabel use of animal drugs. | |
| 21:6.0.1.1.17.2.2.2 | SECTION 530.11
| 530.11 Limitations. | |
| 21:6.0.1.1.17.2.2.3 | SECTION 530.12
| 530.12 Labeling. | |
| 21:6.0.1.1.17.2.2.4 | SECTION 530.13
| 530.13 Extralabel use from compounding of approved new animal and approved human drugs. | |
| 21:6.0.1.1.17.3 | SUBPART C
| Subpart C - Specific Provisions Relating to Extralabel Use of Animal and Human Drugs in Food-Producing Animals | |
| 21:6.0.1.1.17.3.2.1 | SECTION 530.20
| 530.20 Conditions for permitted extralabel animal and human drug use in food-producing animals. | |
| 21:6.0.1.1.17.3.2.2 | SECTION 530.21
| 530.21 Prohibitions for food-producing animals. | |
| 21:6.0.1.1.17.3.2.3 | SECTION 530.22
| 530.22 Safe levels and analytical methods for food-producing animals. | |
| 21:6.0.1.1.17.3.2.4 | SECTION 530.23
| 530.23 Procedure for setting and announcing safe levels. | |
| 21:6.0.1.1.17.3.2.5 | SECTION 530.24
| 530.24 Procedure for announcing analytical methods for drug residue quantification. | |
| 21:6.0.1.1.17.3.2.6 | SECTION 530.25
| 530.25 Orders prohibiting extralabel uses for drugs in food-producing animals. | |
| 21:6.0.1.1.17.4 | SUBPART D
| Subpart D - Extralabel Use of Human and Animal Drugs in Animals Not Intended for Human Consumption | |
| 21:6.0.1.1.17.4.2.1 | SECTION 530.30
| 530.30 Extralabel drug use in nonfood animals. | |
| 21:6.0.1.1.17.5 | SUBPART E
| Subpart E - Safe Levels for Extralabel Use of Drugs in Animals and Drugs Prohibited From Extralabel Use in Animals | |
| 21:6.0.1.1.17.5.2.1 | SECTION 530.40
| 530.40 Safe levels and availability of analytical methods. | |
| 21:6.0.1.1.17.5.2.2 | SECTION 530.41
| 530.41 Drugs prohibited for extralabel use in animals. | |
| 21:6.0.1.1.18 | PART 556
| PART 556 - TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD | |
| 21:6.0.1.1.18.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.18.1.2.1 | SECTION 556.1
| 556.1 Scope. | |
| 21:6.0.1.1.18.1.2.2 | SECTION 556.3
| 556.3 Definitions. | |
| 21:6.0.1.1.18.1.2.3 | SECTION 556.5
| 556.5 General considerations. | |
| 21:6.0.1.1.18.2 | SUBPART B
| Subpart B - Specific Tolerances for Residues of Approved and Conditionally Approved New Animal Drugs | |
| 21:6.0.1.1.18.2.2.1 | SECTION 556.34
| 556.34 Albendazole. | |
| 21:6.0.1.1.18.2.2.2 | SECTION 556.36
| 556.36 Altrenogest. | |
| 21:6.0.1.1.18.2.2.3 | SECTION 556.38
| 556.38 Amoxicillin. | |
| 21:6.0.1.1.18.2.2.4 | SECTION 556.40
| 556.40 Ampicillin. | |
| 21:6.0.1.1.18.2.2.5 | SECTION 556.50
| 556.50 Amprolium. | |
| 21:6.0.1.1.18.2.2.6 | SECTION 556.52
| 556.52 Apramycin. | |
| 21:6.0.1.1.18.2.2.7 | SECTION 556.60
| 556.60 Avilamycin. | |
| 21:6.0.1.1.18.2.2.8 | SECTION 556.68
| 556.68 Azaperone. | |
| 21:6.0.1.1.18.2.2.9 | SECTION 556.70
| 556.70 Bacitracin. | |
| 21:6.0.1.1.18.2.2.10 | SECTION 556.75
| 556.75 Bambermycins. | |
| 21:6.0.1.1.18.2.2.11 | SECTION 556.100
| 556.100 Carbadox. | |
| 21:6.0.1.1.18.2.2.12 | SECTION 556.110
| 556.110 Carbomycin. | |
| 21:6.0.1.1.18.2.2.13 | SECTION 556.113
| 556.113 Ceftiofur. | |
| 21:6.0.1.1.18.2.2.14 | SECTION 556.115
| 556.115 Cephapirin. | |
| 21:6.0.1.1.18.2.2.15 | SECTION 556.118
| 556.118 Chloramine-T. | |
| 21:6.0.1.1.18.2.2.16 | SECTION 556.120
| 556.120 Chlorhexidine. | |
| 21:6.0.1.1.18.2.2.17 | SECTION 556.150
| 556.150 Chlortetracycline. | |
| 21:6.0.1.1.18.2.2.18 | SECTION 556.160
| 556.160 Clopidol. | |
| 21:6.0.1.1.18.2.2.19 | SECTION 556.163
| 556.163 Clorsulon. | |
| 21:6.0.1.1.18.2.2.20 | SECTION 556.165
| 556.165 Cloxacillin. | |
| 21:6.0.1.1.18.2.2.21 | SECTION 556.167
| 556.167 Colistimethate. | |
| 21:6.0.1.1.18.2.2.22 | SECTION 556.169
| 556.169 Danofloxacin. | |
| 21:6.0.1.1.18.2.2.23 | SECTION 556.170
| 556.170 Decoquinate. | |
| 21:6.0.1.1.18.2.2.24 | SECTION 556.180
| 556.180 Dichlorvos. | |
| 21:6.0.1.1.18.2.2.25 | SECTION 556.185
| 556.185 Diclazuril. | |
| 21:6.0.1.1.18.2.2.26 | SECTION 556.200
| 556.200 Dihydrostreptomycin. | |
| 21:6.0.1.1.18.2.2.27 | SECTION 556.222
| 556.222 Doramectin. | |
| 21:6.0.1.1.18.2.2.28 | SECTION 556.224
| 556.224 Efrotomycin. | |
| 21:6.0.1.1.18.2.2.29 | SECTION 556.226
| 556.226 Enrofloxacin. | |
| 21:6.0.1.1.18.2.2.30 | SECTION 556.227
| 556.227 Eprinomectin. | |
| 21:6.0.1.1.18.2.2.31 | SECTION 556.230
| 556.230 Erythromycin. | |
| 21:6.0.1.1.18.2.2.32 | SECTION 556.240
| 556.240 Estradiol and related esters. | |
| 21:6.0.1.1.18.2.2.33 | SECTION 556.260
| 556.260 Ethopabate. | |
| 21:6.0.1.1.18.2.2.34 | SECTION 556.273
| 556.273 Famphur. | |
| 21:6.0.1.1.18.2.2.35 | SECTION 556.275
| 556.275 Fenbendazole. | |
| 21:6.0.1.1.18.2.2.36 | SECTION 556.277
| 556.277 Fenprostalene. | |
| 21:6.0.1.1.18.2.2.37 | SECTION 556.280
| 556.280 Fenthion. | |
| 21:6.0.1.1.18.2.2.38 | SECTION 556.283
| 556.283 Florfenicol. | |
| 21:6.0.1.1.18.2.2.39 | SECTION 556.286
| 556.286 Flunixin. | |
| 21:6.0.1.1.18.2.2.40 | SECTION 556.292
| 556.292 Gamithromycin. | |
| 21:6.0.1.1.18.2.2.41 | SECTION 556.300
| 556.300 Gentamicin. | |
| 21:6.0.1.1.18.2.2.42 | SECTION 556.304
| 556.304 Gonadotropin. | |
| 21:6.0.1.1.18.2.2.43 | SECTION 556.308
| 556.308 Halofuginone. | |
| 21:6.0.1.1.18.2.2.44 | SECTION 556.310
| 556.310 Haloxon. | |
| 21:6.0.1.1.18.2.2.45 | SECTION 556.316
| 556.316 Hetacillin. | |
| 21:6.0.1.1.18.2.2.46 | SECTION 556.330
| 556.330 Hygromycin B. | |
| 21:6.0.1.1.18.2.2.47 | SECTION 556.344
| 556.344 Ivermectin. | |
| 21:6.0.1.1.18.2.2.48 | SECTION 556.346
| 556.346 Laidlomycin. | |
| 21:6.0.1.1.18.2.2.49 | SECTION 556.347
| 556.347 Lasalocid. | |
| 21:6.0.1.1.18.2.2.50 | SECTION 556.350
| 556.350 Levamisole. | |
| 21:6.0.1.1.18.2.2.51 | SECTION 556.360
| 556.360 Lincomycin. | |
| 21:6.0.1.1.18.2.2.52 | SECTION 556.370
| 556.370 Lubabegron. | |
| 21:6.0.1.1.18.2.2.53 | SECTION 556.375
| 556.375 Maduramicin. | |
| 21:6.0.1.1.18.2.2.54 | SECTION 556.380
| 556.380 Melengestrol. | |
| 21:6.0.1.1.18.2.2.55 | SECTION 556.410
| 556.410 Metoserpate. | |
| 21:6.0.1.1.18.2.2.56 | SECTION 556.420
| 556.420 Monensin. | |
| 21:6.0.1.1.18.2.2.57 | SECTION 556.425
| 556.425 Morantel. | |
| 21:6.0.1.1.18.2.2.58 | SECTION 556.426
| 556.426 Moxidectin. | |
| 21:6.0.1.1.18.2.2.59 | SECTION 556.428
| 556.428 Narasin. | |
| 21:6.0.1.1.18.2.2.60 | SECTION 556.430
| 556.430 Neomycin. | |
| 21:6.0.1.1.18.2.2.61 | SECTION 556.445
| 556.445 Nicarbazin. | |
| 21:6.0.1.1.18.2.2.62 | SECTION 556.460
| 556.460 Novobiocin. | |
| 21:6.0.1.1.18.2.2.63 | SECTION 556.470
| 556.470 Nystatin. | |
| 21:6.0.1.1.18.2.2.64 | SECTION 556.490
| 556.490 Ormetoprim. | |
| 21:6.0.1.1.18.2.2.65 | SECTION 556.495
| 556.495 Oxfendazole. | |
| 21:6.0.1.1.18.2.2.66 | SECTION 556.500
| 556.500 Oxytetracycline. | |
| 21:6.0.1.1.18.2.2.67 | SECTION 556.510
| 556.510 Penicillin. | |
| 21:6.0.1.1.18.2.2.68 | SECTION 556.515
| 556.515 Pirlimycin. | |
| 21:6.0.1.1.18.2.2.69 | SECTION 556.517
| 556.517 Poloxalene. | |
| 21:6.0.1.1.18.2.2.70 | SECTION 556.540
| 556.540 Progesterone. | |
| 21:6.0.1.1.18.2.2.71 | SECTION 556.560
| 556.560 Pyrantel. | |
| 21:6.0.1.1.18.2.2.72 | SECTION 556.570
| 556.570 Ractopamine. | |
| 21:6.0.1.1.18.2.2.73 | SECTION 556.580
| 556.580 Robenidine. | |
| 21:6.0.1.1.18.2.2.74 | SECTION 556.592
| 556.592 Salinomycin. | |
| 21:6.0.1.1.18.2.2.75 | SECTION 556.597
| 556.597 Semduramicin. | |
| 21:6.0.1.1.18.2.2.76 | SECTION 556.600
| 556.600 Spectinomycin. | |
| 21:6.0.1.1.18.2.2.77 | SECTION 556.610
| 556.610 Streptomycin. | |
| 21:6.0.1.1.18.2.2.78 | SECTION 556.620
| 556.620 Sulfabromomethazine. | |
| 21:6.0.1.1.18.2.2.79 | SECTION 556.625
| 556.625 Sulfachloropyrazine. | |
| 21:6.0.1.1.18.2.2.80 | SECTION 556.630
| 556.630 Sulfachlorpyridazine. | |
| 21:6.0.1.1.18.2.2.81 | SECTION 556.640
| 556.640 Sulfadimethoxine. | |
| 21:6.0.1.1.18.2.2.82 | SECTION 556.650
| 556.650 Sulfaethoxypyridazine. | |
| 21:6.0.1.1.18.2.2.83 | SECTION 556.660
| 556.660 Sulfamerazine. | |
| 21:6.0.1.1.18.2.2.84 | SECTION 556.670
| 556.670 Sulfamethazine. | |
| 21:6.0.1.1.18.2.2.85 | SECTION 556.685
| 556.685 Sulfaquinoxaline. | |
| 21:6.0.1.1.18.2.2.86 | SECTION 556.700
| 556.700 Sulfomyxin. | |
| 21:6.0.1.1.18.2.2.87 | SECTION 556.710
| 556.710 Testosterone. | |
| 21:6.0.1.1.18.2.2.88 | SECTION 556.720
| 556.720 Tetracycline. | |
| 21:6.0.1.1.18.2.2.89 | SECTION 556.730
| 556.730 Thiabendazole. | |
| 21:6.0.1.1.18.2.2.90 | SECTION 556.732
| 556.732 Tiamulin. | |
| 21:6.0.1.1.18.2.2.91 | SECTION 556.733
| 556.733 Tildipirosin. | |
| 21:6.0.1.1.18.2.2.92 | SECTION 556.735
| 556.735 Tilmicosin. | |
| 21:6.0.1.1.18.2.2.93 | SECTION 556.739
| 556.739 Trenbolone. | |
| 21:6.0.1.1.18.2.2.94 | SECTION 556.741
| 556.741 Tripelennamine. | |
| 21:6.0.1.1.18.2.2.95 | SECTION 556.745
| 556.745 Tulathromycin. | |
| 21:6.0.1.1.18.2.2.96 | SECTION 556.746
| 556.746 Tylosin. | |
| 21:6.0.1.1.18.2.2.97 | SECTION 556.748
| 556.748 Tylvalosin. | |
| 21:6.0.1.1.18.2.2.98 | SECTION 556.750
| 556.750 Virginiamycin. | |
| 21:6.0.1.1.18.2.2.99 | SECTION 556.760
| 556.760 Zeranol. | |
| 21:6.0.1.1.18.2.2.100 | SECTION 556.765
| 556.765 Zilpaterol. | |
| 21:6.0.1.1.18.2.2.101 | SECTION 556.770
| 556.770 Zoalene. | |
| 21:6.0.1.1.19 | PART 558
| PART 558 - NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS | |
| 21:6.0.1.1.19.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.19.1.2.1 | SECTION 558.3
| 558.3 Definitions and general considerations applicable to this part. | |
| 21:6.0.1.1.19.1.2.2 | SECTION 558.4
| 558.4 Requirement of a medicated feed mill license. | |
| 21:6.0.1.1.19.1.2.3 | SECTION 558.5
| 558.5 Requirements for liquid medicated feed. | |
| 21:6.0.1.1.19.1.2.4 | SECTION 558.6
| 558.6 Veterinary feed directive drugs. | |
| 21:6.0.1.1.19.2 | SUBPART B
| Subpart B - Specific New Animal Drugs for Use in Animal Feeds | |
| 21:6.0.1.1.19.2.2.1 | SECTION 558.55
| 558.55 Amprolium. | |
| 21:6.0.1.1.19.2.2.2 | SECTION 558.58
| 558.58 Amprolium and ethopabate. | |
| 21:6.0.1.1.19.2.2.3 | SECTION 558.59
| 558.59 Apramycin. | |
| 21:6.0.1.1.19.2.2.4 | SECTION 558.68
| 558.68 Avilamycin. | |
| 21:6.0.1.1.19.2.2.5 | SECTION 558.76
| 558.76 Bacitracin methylenedisalicylate. | |
| 21:6.0.1.1.19.2.2.6 | SECTION 558.78
| 558.78 Bacitracin zinc. | |
| 21:6.0.1.1.19.2.2.7 | SECTION 558.95
| 558.95 Bambermycins. | |
| 21:6.0.1.1.19.2.2.8 | SECTION 558.115
| 558.115 Carbadox. | |
| 21:6.0.1.1.19.2.2.9 | SECTION 558.128
| 558.128 Chlortetracycline. | |
| 21:6.0.1.1.19.2.2.10 | SECTION 558.140
| 558.140 Chlortetracycline and sulfamethazine. | |
| 21:6.0.1.1.19.2.2.11 | SECTION 558.175
| 558.175 Clopidol. | |
| 21:6.0.1.1.19.2.2.12 | SECTION 558.195
| 558.195 Decoquinate. | |
| 21:6.0.1.1.19.2.2.13 | SECTION 558.198
| 558.198 Dichlorvos. | |
| 21:6.0.1.1.19.2.2.14 | SECTION 558.205
| 558.205 Diclazuril. | |
| 21:6.0.1.1.19.2.2.15 | SECTION 558.235
| 558.235 Efrotomycin. | |
| 21:6.0.1.1.19.2.2.16 | SECTION 558.248
| 558.248 Erythromycin. | |
| 21:6.0.1.1.19.2.2.17 | SECTION 558.254
| 558.254 Famphur. | |
| 21:6.0.1.1.19.2.2.18 | SECTION 558.258
| 558.258 Fenbendazole. | |
| 21:6.0.1.1.19.2.2.19 | SECTION 558.261
| 558.261 Florfenicol. | |
| 21:6.0.1.1.19.2.2.20 | SECTION 558.265
| 558.265 Halofuginone. | |
| 21:6.0.1.1.19.2.2.21 | SECTION 558.274
| 558.274 Hygromycin B. | |
| 21:6.0.1.1.19.2.2.22 | SECTION 558.295
| 558.295 Iodinated casein. | |
| 21:6.0.1.1.19.2.2.23 | SECTION 558.300
| 558.300 Ivermectin. | |
| 21:6.0.1.1.19.2.2.24 | SECTION 558.305
| 558.305 Laidlomycin. | |
| 21:6.0.1.1.19.2.2.25 | SECTION 558.311
| 558.311 Lasalocid. | |
| 21:6.0.1.1.19.2.2.26 | SECTION 558.325
| 558.325 Lincomycin. | |
| 21:6.0.1.1.19.2.2.27 | SECTION 558.330
| 558.330 Lubabegron. | |
| 21:6.0.1.1.19.2.2.28 | SECTION 558.340
| 558.340 Maduramicin. | |
| 21:6.0.1.1.19.2.2.29 | SECTION 558.342
| 558.342 Melengestrol. | |
| 21:6.0.1.1.19.2.2.30 | SECTION 558.348
| 558.348 Mibolerone. | |
| 21:6.0.1.1.19.2.2.31 | SECTION 558.355
| 558.355 Monensin. | |
| 21:6.0.1.1.19.2.2.32 | SECTION 558.360
| 558.360 Morantel. | |
| 21:6.0.1.1.19.2.2.33 | SECTION 558.363
| 558.363 Narasin. | |
| 21:6.0.1.1.19.2.2.34 | SECTION 558.364
| 558.364 Narasin and nicarbazin. | |
| 21:6.0.1.1.19.2.2.35 | SECTION 558.365
| 558.365 Neomycin sulfate. | |
| 21:6.0.1.1.19.2.2.36 | SECTION 558.366
| 558.366 Nicarbazin. | |
| 21:6.0.1.1.19.2.2.37 | SECTION 558.415
| 558.415 Novobiocin. | |
| 21:6.0.1.1.19.2.2.38 | SECTION 558.430
| 558.430 Nystatin. | |
| 21:6.0.1.1.19.2.2.39 | SECTION 558.450
| 558.450 Oxytetracycline. | |
| 21:6.0.1.1.19.2.2.40 | SECTION 558.455
| 558.455 Oxytetracycline and neomycin. | |
| 21:6.0.1.1.19.2.2.41 | SECTION 558.464
| 558.464 Poloxalene. | |
| 21:6.0.1.1.19.2.2.42 | SECTION 558.465
| 558.465 Poloxalene. | |
| 21:6.0.1.1.19.2.2.43 | SECTION 558.485
| 558.485 Pyrantel. | |
| 21:6.0.1.1.19.2.2.44 | SECTION 558.500
| 558.500 Ractopamine. | |
| 21:6.0.1.1.19.2.2.45 | SECTION 558.515
| 558.515 Robenidine. | |
| 21:6.0.1.1.19.2.2.46 | SECTION 558.550
| 558.550 Salinomycin. | |
| 21:6.0.1.1.19.2.2.47 | SECTION 558.555
| 558.555 Semduramicin. | |
| 21:6.0.1.1.19.2.2.48 | SECTION 558.575
| 558.575 Sulfadimethoxine and ormetoprim. | |
| 21:6.0.1.1.19.2.2.49 | SECTION 558.582
| 558.582 Sulfamerazine. | |
| 21:6.0.1.1.19.2.2.50 | SECTION 558.586
| 558.586 Sulfaquinoxaline. | |
| 21:6.0.1.1.19.2.2.51 | SECTION 558.600
| 558.600 Thiabendazole. | |
| 21:6.0.1.1.19.2.2.52 | SECTION 558.612
| 558.612 Tiamulin. | |
| 21:6.0.1.1.19.2.2.53 | SECTION 558.618
| 558.618 Tilmicosin. | |
| 21:6.0.1.1.19.2.2.54 | SECTION 558.625
| 558.625 Tylosin. | |
| 21:6.0.1.1.19.2.2.55 | SECTION 558.630
| 558.630 Tylosin and sulfamethazine. | |
| 21:6.0.1.1.19.2.2.56 | SECTION 558.633
| 558.633 Tylvalosin. | |
| 21:6.0.1.1.19.2.2.57 | SECTION 558.635
| 558.635 Virginiamycin. | |
| 21:6.0.1.1.19.2.2.58 | SECTION 558.665
| 558.665 Zilpaterol. | |
| 21:6.0.1.1.19.2.2.59 | SECTION 558.680
| 558.680 Zoalene. | |
| 21:6.0.1.1.20 | PART 564
| PART 564 [RESERVED] | |
| 21:6.0.1.1.21 | PART 570
| PART 570 - FOOD ADDITIVES | |
| 21:6.0.1.1.21.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.21.1.2.1 | SECTION 570.3
| 570.3 Definitions. | |
| 21:6.0.1.1.21.1.2.2 | SECTION 570.6
| 570.6 Opinion letters on food additive status. | |
| 21:6.0.1.1.21.1.2.3 | SECTION 570.13
| 570.13 Indirect food additives resulting from packaging materials prior sanctioned for animal feed and pet food. | |
| 21:6.0.1.1.21.1.2.4 | SECTION 570.14
| 570.14 Indirect food additives resulting from packaging materials for animal feed and pet food. | |
| 21:6.0.1.1.21.1.2.5 | SECTION 570.15
| 570.15 Adoption of regulation on initiative of Commissioner. | |
| 21:6.0.1.1.21.1.2.6 | SECTION 570.17
| 570.17 Exemption for investigational use and procedure for obtaining authorization to market edible products from experimental animals. | |
| 21:6.0.1.1.21.1.2.7 | SECTION 570.18
| 570.18 Tolerances for related food additives. | |
| 21:6.0.1.1.21.1.2.8 | SECTION 570.19
| 570.19 Pesticide chemicals in processed foods. | |
| 21:6.0.1.1.21.2 | SUBPART B
| Subpart B - Food Additive Safety | |
| 21:6.0.1.1.21.2.2.1 | SECTION 570.20
| 570.20 General principles for evaluating the safety of food additives. | |
| 21:6.0.1.1.21.2.2.2 | SECTION 570.30
| 570.30 Eligibility for classification as generally recognized as safe (GRAS). | |
| 21:6.0.1.1.21.2.2.3 | SECTION 570.35
| 570.35 Affirmation of generally recognized as safe (GRAS) status. | |
| 21:6.0.1.1.21.2.2.4 | SECTION 570.38
| 570.38 Determination of food additive status. | |
| 21:6.0.1.1.21.3 | SUBPART C
| Subparts C-D [Reserved] | |
| 21:6.0.1.1.21.4 | SUBPART E
| Subpart E - Generally Recognized as Safe (GRAS) Notice | |
| 21:6.0.1.1.21.4.2.1 | SECTION 570.203
| 570.203 Definitions. | |
| 21:6.0.1.1.21.4.2.2 | SECTION 570.205
| 570.205 Opportunity to submit a GRAS notice. | |
| 21:6.0.1.1.21.4.2.3 | SECTION 570.210
| 570.210 How to send your GRAS notice to FDA. | |
| 21:6.0.1.1.21.4.2.4 | SECTION 570.215
| 570.215 Incorporation into a GRAS notice. | |
| 21:6.0.1.1.21.4.2.5 | SECTION 570.220
| 570.220 General requirements applicable to a GRAS notice. | |
| 21:6.0.1.1.21.4.2.6 | SECTION 570.225
| 570.225 Part 1 of a GRAS notice: Signed statements and certification. | |
| 21:6.0.1.1.21.4.2.7 | SECTION 570.230
| 570.230 Part 2 of a GRAS notice: Identity, method of manufacture, specifications, and physical or technical effect. | |
| 21:6.0.1.1.21.4.2.8 | SECTION 570.235
| 570.235 Part 3 of a GRAS notice: Target animal and human exposures. | |
| 21:6.0.1.1.21.4.2.9 | SECTION 570.240
| 570.240 Part 4 of a GRAS notice: Self-limiting levels of use. | |
| 21:6.0.1.1.21.4.2.10 | SECTION 570.245
| 570.245 Part 5 of a GRAS notice: Experience based on common use in food before 1958. | |
| 21:6.0.1.1.21.4.2.11 | SECTION 570.250
| 570.250 Part 6 of a GRAS notice: Narrative. | |
| 21:6.0.1.1.21.4.2.12 | SECTION 570.255
| 570.255 Part 7 of a GRAS notice: List of supporting data and information in your GRAS notice. | |
| 21:6.0.1.1.21.4.2.13 | SECTION 570.260
| 570.260 Steps you may take before FDA responds to your GRAS notice. | |
| 21:6.0.1.1.21.4.2.14 | SECTION 570.265
| 570.265 What FDA will do with a GRAS notice. | |
| 21:6.0.1.1.21.4.2.15 | SECTION 570.275
| 570.275 Public disclosure of a GRAS notice. | |
| 21:6.0.1.1.21.4.2.16 | SECTION 570.280
| 570.280 Submission of a supplement. | |
| 21:6.0.1.1.22 | PART 571
| PART 571 - FOOD ADDITIVE PETITIONS | |
| 21:6.0.1.1.22.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.22.1.2.1 | SECTION 571.1
| 571.1 Petitions. | |
| 21:6.0.1.1.22.1.2.2 | SECTION 571.6
| 571.6 Amendment of petition. | |
| 21:6.0.1.1.22.1.2.3 | SECTION 571.7
| 571.7 Withdrawal of petition without prejudice. | |
| 21:6.0.1.1.22.2 | SUBPART B
| Subpart B - Administrative Actions on Applications | |
| 21:6.0.1.1.22.2.2.1 | SECTION 571.100
| 571.100 Regulation based on petition. | |
| 21:6.0.1.1.22.2.2.2 | SECTION 571.102
| 571.102 Effective date of regulation. | |
| 21:6.0.1.1.22.2.2.3 | SECTION 571.110
| 571.110 Procedure for objections and hearings. | |
| 21:6.0.1.1.22.2.2.4 | SECTION 571.115
| 571.115 Application of the cancer clause of section 409 of the act. | |
| 21:6.0.1.1.22.2.2.5 | SECTION 571.130
| 571.130 Procedure for amending and repealing tolerances or exemptions from tolerances. | |
| 21:6.0.1.1.23 | PART 573
| PART 573 - FOOD ADDITIVES PERMITTED IN FEED AND DRINKING WATER OF ANIMALS | |
| 21:6.0.1.1.23.1 | SUBPART A
| Subpart A [Reserved] | |
| 21:6.0.1.1.23.2 | SUBPART B
| Subpart B - Food Additive Listing | |
| 21:6.0.1.1.23.2.2.1 | SECTION 573.120
| 573.120 Acrylamide-acrylic acid resin. | |
| 21:6.0.1.1.23.2.2.2 | SECTION 573.130
| 573.130 Aminoglycoside 3′-phospho- transferase II. | |
| 21:6.0.1.1.23.2.2.3 | SECTION 573.140
| 573.140 Ammoniated cottonseed meal. | |
| 21:6.0.1.1.23.2.2.4 | SECTION 573.160
| 573.160 Ammoniated rice hulls. | |
| 21:6.0.1.1.23.2.2.5 | SECTION 573.170
| 573.170 Ammonium formate. | |
| 21:6.0.1.1.23.2.2.6 | SECTION 573.180
| 573.180 Anhydrous ammonia. | |
| 21:6.0.1.1.23.2.2.7 | SECTION 573.200
| 573.200 Condensed animal protein hydrolysate. | |
| 21:6.0.1.1.23.2.2.8 | SECTION 573.210
| 573.210 Benzoic acid. | |
| 21:6.0.1.1.23.2.2.9 | SECTION 573.220
| 573.220 Feed-grade biuret. | |
| 21:6.0.1.1.23.2.2.10 | SECTION 573.225
| 573.225 1,3-Butylene glycol. | |
| 21:6.0.1.1.23.2.2.11 | SECTION 573.240
| 573.240 Calcium periodate. | |
| 21:6.0.1.1.23.2.2.12 | SECTION 573.260
| 573.260 Calcium silicate. | |
| 21:6.0.1.1.23.2.2.13 | SECTION 573.280
| 573.280 Feed-grade calcium stearate and sodium stearate. | |
| 21:6.0.1.1.23.2.2.14 | SECTION 573.300
| 573.300 Choline xanthate. | |
| 21:6.0.1.1.23.2.2.15 | SECTION 573.304
| 573.304 Chromium Propionate. | |
| 21:6.0.1.1.23.2.2.16 | SECTION 573.310
| 573.310 Crambe meal, heat toasted. | |
| 21:6.0.1.1.23.2.2.17 | SECTION 573.320
| 573.320 Diammonium phosphate. | |
| 21:6.0.1.1.23.2.2.18 | SECTION 573.340
| 573.340 Diatomaceous earth. | |
| 21:6.0.1.1.23.2.2.19 | SECTION 573.360
| 573.360 Disodium EDTA. | |
| 21:6.0.1.1.23.2.2.20 | SECTION 573.380
| 573.380 Ethoxyquin in animal feeds. | |
| 21:6.0.1.1.23.2.2.21 | SECTION 573.400
| 573.400 Ethoxyquin in certain dehydrated forage crops. | |
| 21:6.0.1.1.23.2.2.22 | SECTION 573.420
| 573.420 Ethyl cellulose. | |
| 21:6.0.1.1.23.2.2.23 | SECTION 573.440
| 573.440 Ethylene dichloride. | |
| 21:6.0.1.1.23.2.2.24 | SECTION 573.450
| 573.450 Fermented ammoniated condensed whey. | |
| 21:6.0.1.1.23.2.2.25 | SECTION 573.460
| 573.460 Formaldehyde. | |
| 21:6.0.1.1.23.2.2.26 | SECTION 573.480
| 573.480 Formic acid. | |
| 21:6.0.1.1.23.2.2.27 | SECTION 573.490
| 573.490 Gamma-linolenic acid safflower meal. | |
| 21:6.0.1.1.23.2.2.28 | SECTION 573.492
| 573.492 Gamma-linolenic acid safflower oil. | |
| 21:6.0.1.1.23.2.2.29 | SECTION 573.496
| 573.496 Guanidinoacetic acid. | |
| 21:6.0.1.1.23.2.2.30 | SECTION 573.500
| 573.500 Condensed, extracted glutamic acid fermentation product. | |
| 21:6.0.1.1.23.2.2.31 | SECTION 573.520
| 573.520 Hemicellulose extract. | |
| 21:6.0.1.1.23.2.2.32 | SECTION 573.530
| 573.530 Hydrogenated corn syrup. | |
| 21:6.0.1.1.23.2.2.33 | SECTION 573.540
| 573.540 Hydrolyzed leather meal. | |
| 21:6.0.1.1.23.2.2.34 | SECTION 573.550
| 573.550 25-hydroxyvitamin D3. | |
| 21:6.0.1.1.23.2.2.35 | SECTION 573.560
| 573.560 Iron ammonium citrate. | |
| 21:6.0.1.1.23.2.2.36 | SECTION 573.580
| 573.580 Iron-choline citrate complex. | |
| 21:6.0.1.1.23.2.2.37 | SECTION 573.600
| 573.600 Lignin sulfonates. | |
| 21:6.0.1.1.23.2.2.38 | SECTION 573.615
| 573.615 Marine microalgae. | |
| 21:6.0.1.1.23.2.2.39 | SECTION 573.620
| 573.620 Menadione dimethylpyrimidinol bisulfite. | |
| 21:6.0.1.1.23.2.2.40 | SECTION 573.625
| 573.625 Menadione nicotinamide bisulfite. | |
| 21:6.0.1.1.23.2.2.41 | SECTION 573.637
| 573.637 Methyl esters of conjugated linoleic acid (cis-9, trans-11 and trans-10, cis-12-octadecadienoic acids). | |
| 21:6.0.1.1.23.2.2.42 | SECTION 573.640
| 573.640 Methyl esters of higher fatty acids. | |
| 21:6.0.1.1.23.2.2.43 | SECTION 573.660
| 573.660 Methyl glucoside-coconut oil ester. | |
| 21:6.0.1.1.23.2.2.44 | SECTION 573.680
| 573.680 Mineral oil. | |
| 21:6.0.1.1.23.2.2.45 | SECTION 573.685
| 573.685 Natamycin. | |
| 21:6.0.1.1.23.2.2.46 | SECTION 573.696
| 573.696 Feed grade sodium formate. | |
| 21:6.0.1.1.23.2.2.47 | SECTION 573.700
| 573.700 Sodium nitrite. | |
| 21:6.0.1.1.23.2.2.48 | SECTION 573.720
| 573.720 Petrolatum. | |
| 21:6.0.1.1.23.2.2.49 | SECTION 573.740
| 573.740 Odorless light petroleum hydrocarbons. | |
| 21:6.0.1.1.23.2.2.50 | SECTION 573.750
| 573.750 Pichia pastoris dried yeast. | |
| 21:6.0.1.1.23.2.2.51 | SECTION 573.760
| 573.760 Poloxalene. | |
| 21:6.0.1.1.23.2.2.52 | SECTION 573.780
| 573.780 Polyethylene. | |
| 21:6.0.1.1.23.2.2.53 | SECTION 573.800
| 573.800 Polyethylene glycol (400) mono- and dioleate. | |
| 21:6.0.1.1.23.2.2.54 | SECTION 573.820
| 573.820 Polyoxyethylene glycol (400) mono- and dioleates. | |
| 21:6.0.1.1.23.2.2.55 | SECTION 573.840
| 573.840 Polysorbate 60. | |
| 21:6.0.1.1.23.2.2.56 | SECTION 573.860
| 573.860 Polysorbate 80. | |
| 21:6.0.1.1.23.2.2.57 | SECTION 573.870
| 573.870 Poly(2-vinylpyridine-co-styrene). | |
| 21:6.0.1.1.23.2.2.58 | SECTION 573.880
| 573.880 Normal propyl alcohol. | |
| 21:6.0.1.1.23.2.2.59 | SECTION 573.900
| 573.900 Pyrophyllite. | |
| 21:6.0.1.1.23.2.2.60 | SECTION 573.914
| 573.914 Salts of volatile fatty acids. | |
| 21:6.0.1.1.23.2.2.61 | SECTION 573.920
| 573.920 Selenium. | |
| 21:6.0.1.1.23.2.2.62 | SECTION 573.940
| 573.940 Silicon dioxide. | |
| 21:6.0.1.1.23.2.2.63 | SECTION 573.960
| 573.960 Sorbitan monostearate. | |
| 21:6.0.1.1.23.2.2.64 | SECTION 573.980
| 573.980 Taurine. | |
| 21:6.0.1.1.23.2.2.65 | SECTION 573.1000
| 573.1000 Verxite. | |
| 21:6.0.1.1.23.2.2.66 | SECTION 573.1010
| 573.1010 Xanthan gum. | |
| 21:6.0.1.1.23.2.2.67 | SECTION 573.1020
| 573.1020 Yellow prussiate of soda. | |
| 21:6.0.1.1.24 | PART 579
| PART 579 - IRRADIATION IN THE PRODUCTION, PROCESSING, AND HANDLING OF ANIMAL FEED AND PET FOOD | |
| 21:6.0.1.1.24.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.24.1.2.1 | SECTION 579.12
| 579.12 Incorporation of regulations in part 179. | |
| 21:6.0.1.1.24.2 | SUBPART B
| Subpart B - Radiation and Radiation Sources | |
| 21:6.0.1.1.24.2.2.1 | SECTION 579.22
| 579.22 Ionizing radiation for treatment of animal diets. | |
| 21:6.0.1.1.24.2.2.2 | SECTION 579.40
| 579.40 Ionizing radiation for the treatment of poultry feed and poultry feed ingredients. | |
| 21:6.0.1.1.25 | PART 582
| PART 582 - SUBSTANCES GENERALLY RECOGNIZED AS SAFE | |
| 21:6.0.1.1.25.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.25.1.2.1 | SECTION 582.1
| 582.1 Substances that are generally recognized as safe. | |
| 21:6.0.1.1.25.1.2.2 | SECTION 582.10
| 582.10 Spices and other natural seasonings and flavorings. | |
| 21:6.0.1.1.25.1.2.3 | SECTION 582.20
| 582.20 Essential oils, oleoresins (solvent-free), and natural extractives (including distillates). | |
| 21:6.0.1.1.25.1.2.4 | SECTION 582.30
| 582.30 Natural substances used in conjunction with spices and other natural seasonings and flavorings. | |
| 21:6.0.1.1.25.1.2.5 | SECTION 582.40
| 582.40 Natural extractives (solvent-free) used in conjunction with spices, seasonings, and flavorings. | |
| 21:6.0.1.1.25.1.2.6 | SECTION 582.50
| 582.50 Certain other spices, seasonings, essential oils, oleoresins, and natural extracts. | |
| 21:6.0.1.1.25.1.2.7 | SECTION 582.60
| 582.60 Synthetic flavoring substances and adjuvants. | |
| 21:6.0.1.1.25.1.2.8 | SECTION 582.80
| 582.80 Trace minerals added to animal feeds. | |
| 21:6.0.1.1.25.1.2.9 | SECTION 582.99
| 582.99 Adjuvants for pesticide chemicals. | |
| 21:6.0.1.1.25.2 | SUBPART B
| Subpart B - General Purpose Food Additives | |
| 21:6.0.1.1.25.2.2.1 | SECTION 582.1005
| 582.1005 Acetic acid. | |
| 21:6.0.1.1.25.2.2.2 | SECTION 582.1009
| 582.1009 Adipic acid. | |
| 21:6.0.1.1.25.2.2.3 | SECTION 582.1033
| 582.1033 Citric acid. | |
| 21:6.0.1.1.25.2.2.4 | SECTION 582.1057
| 582.1057 Hydrochloric acid. | |
| 21:6.0.1.1.25.2.2.5 | SECTION 582.1061
| 582.1061 Lactic acid. | |
| 21:6.0.1.1.25.2.2.6 | SECTION 582.1069
| 582.1069 Malic acid. | |
| 21:6.0.1.1.25.2.2.7 | SECTION 582.1073
| 582.1073 Phosphoric acid. | |
| 21:6.0.1.1.25.2.2.8 | SECTION 582.1077
| 582.1077 Potassium acid tartrate. | |
| 21:6.0.1.1.25.2.2.9 | SECTION 582.1087
| 582.1087 Sodium acid pyrophosphate. | |
| 21:6.0.1.1.25.2.2.10 | SECTION 582.1091
| 582.1091 Succinic acid. | |
| 21:6.0.1.1.25.2.2.11 | SECTION 582.1095
| 582.1095 Sulfuric acid. | |
| 21:6.0.1.1.25.2.2.12 | SECTION 582.1099
| 582.1099 Tartaric acid. | |
| 21:6.0.1.1.25.2.2.13 | SECTION 582.1125
| 582.1125 Aluminum sulfate. | |
| 21:6.0.1.1.25.2.2.14 | SECTION 582.1127
| 582.1127 Aluminum ammonium sulfate. | |
| 21:6.0.1.1.25.2.2.15 | SECTION 582.1129
| 582.1129 Aluminum potassium sulfate. | |
| 21:6.0.1.1.25.2.2.16 | SECTION 582.1131
| 582.1131 Aluminum sodium sulfate. | |
| 21:6.0.1.1.25.2.2.17 | SECTION 582.1135
| 582.1135 Ammonium bicarbonate. | |
| 21:6.0.1.1.25.2.2.18 | SECTION 582.1137
| 582.1137 Ammonium carbonate. | |
| 21:6.0.1.1.25.2.2.19 | SECTION 582.1139
| 582.1139 Ammonium hydroxide. | |
| 21:6.0.1.1.25.2.2.20 | SECTION 582.1141
| 582.1141 Ammonium phosphate. | |
| 21:6.0.1.1.25.2.2.21 | SECTION 582.1143
| 582.1143 Ammonium sulfate. | |
| 21:6.0.1.1.25.2.2.22 | SECTION 582.1155
| 582.1155 Bentonite. | |
| 21:6.0.1.1.25.2.2.23 | SECTION 582.1165
| 582.1165 Butane. | |
| 21:6.0.1.1.25.2.2.24 | SECTION 582.1191
| 582.1191 Calcium carbonate. | |
| 21:6.0.1.1.25.2.2.25 | SECTION 582.1193
| 582.1193 Calcium chloride. | |
| 21:6.0.1.1.25.2.2.26 | SECTION 582.1195
| 582.1195 Calcium citrate. | |
| 21:6.0.1.1.25.2.2.27 | SECTION 582.1199
| 582.1199 Calcium gluconate. | |
| 21:6.0.1.1.25.2.2.28 | SECTION 582.1205
| 582.1205 Calcium hydroxide. | |
| 21:6.0.1.1.25.2.2.29 | SECTION 582.1207
| 582.1207 Calcium lactate. | |
| 21:6.0.1.1.25.2.2.30 | SECTION 582.1210
| 582.1210 Calcium oxide. | |
| 21:6.0.1.1.25.2.2.31 | SECTION 582.1217
| 582.1217 Calcium phosphate. | |
| 21:6.0.1.1.25.2.2.32 | SECTION 582.1235
| 582.1235 Caramel. | |
| 21:6.0.1.1.25.2.2.33 | SECTION 582.1240
| 582.1240 Carbon dioxide. | |
| 21:6.0.1.1.25.2.2.34 | SECTION 582.1275
| 582.1275 Dextrans. | |
| 21:6.0.1.1.25.2.2.35 | SECTION 582.1320
| 582.1320 Glycerin. | |
| 21:6.0.1.1.25.2.2.36 | SECTION 582.1324
| 582.1324 Glyceryl monostearate. | |
| 21:6.0.1.1.25.2.2.37 | SECTION 582.1355
| 582.1355 Helium. | |
| 21:6.0.1.1.25.2.2.38 | SECTION 582.1366
| 582.1366 Hydrogen peroxide. | |
| 21:6.0.1.1.25.2.2.39 | SECTION 582.1400
| 582.1400 Lecithin. | |
| 21:6.0.1.1.25.2.2.40 | SECTION 582.1425
| 582.1425 Magnesium carbonate. | |
| 21:6.0.1.1.25.2.2.41 | SECTION 582.1428
| 582.1428 Magnesium hydroxide. | |
| 21:6.0.1.1.25.2.2.42 | SECTION 582.1431
| 582.1431 Magnesium oxide. | |
| 21:6.0.1.1.25.2.2.43 | SECTION 582.1480
| 582.1480 Methylcellulose. | |
| 21:6.0.1.1.25.2.2.44 | SECTION 582.1500
| 582.1500 Monoammonium glutamate. | |
| 21:6.0.1.1.25.2.2.45 | SECTION 582.1516
| 582.1516 Monopotassium glutamate. | |
| 21:6.0.1.1.25.2.2.46 | SECTION 582.1540
| 582.1540 Nitrogen. | |
| 21:6.0.1.1.25.2.2.47 | SECTION 582.1585
| 582.1585 Papain. | |
| 21:6.0.1.1.25.2.2.48 | SECTION 582.1613
| 582.1613 Potassium bicarbonate. | |
| 21:6.0.1.1.25.2.2.49 | SECTION 582.1619
| 582.1619 Potassium carbonate. | |
| 21:6.0.1.1.25.2.2.50 | SECTION 582.1625
| 582.1625 Potassium citrate. | |
| 21:6.0.1.1.25.2.2.51 | SECTION 582.1631
| 582.1631 Potassium hydroxide. | |
| 21:6.0.1.1.25.2.2.52 | SECTION 582.1643
| 582.1643 Potassium sulfate. | |
| 21:6.0.1.1.25.2.2.53 | SECTION 582.1655
| 582.1655 Propane. | |
| 21:6.0.1.1.25.2.2.54 | SECTION 582.1666
| 582.1666 Propylene glycol. | |
| 21:6.0.1.1.25.2.2.55 | SECTION 582.1685
| 582.1685 Rennet. | |
| 21:6.0.1.1.25.2.2.56 | SECTION 582.1711
| 582.1711 Silica aerogel. | |
| 21:6.0.1.1.25.2.2.57 | SECTION 582.1721
| 582.1721 Sodium acetate. | |
| 21:6.0.1.1.25.2.2.58 | SECTION 582.1736
| 582.1736 Sodium bicarbonate. | |
| 21:6.0.1.1.25.2.2.59 | SECTION 582.1742
| 582.1742 Sodium carbonate. | |
| 21:6.0.1.1.25.2.2.60 | SECTION 582.1745
| 582.1745 Sodium carboxymethylcellulose. | |
| 21:6.0.1.1.25.2.2.61 | SECTION 582.1748
| 582.1748 Sodium caseinate. | |
| 21:6.0.1.1.25.2.2.62 | SECTION 582.1751
| 582.1751 Sodium citrate. | |
| 21:6.0.1.1.25.2.2.63 | SECTION 582.1763
| 582.1763 Sodium hydroxide. | |
| 21:6.0.1.1.25.2.2.64 | SECTION 582.1775
| 582.1775 Sodium pectinate. | |
| 21:6.0.1.1.25.2.2.65 | SECTION 582.1778
| 582.1778 Sodium phosphate. | |
| 21:6.0.1.1.25.2.2.66 | SECTION 582.1781
| 582.1781 Sodium aluminum phosphate. | |
| 21:6.0.1.1.25.2.2.67 | SECTION 582.1792
| 582.1792 Sodium sesquicarbonate. | |
| 21:6.0.1.1.25.2.2.68 | SECTION 582.1804
| 582.1804 Sodium potassium tartrate. | |
| 21:6.0.1.1.25.2.2.69 | SECTION 582.1810
| 582.1810 Sodium tripolyphosphate. | |
| 21:6.0.1.1.25.2.2.70 | SECTION 582.1901
| 582.1901 Triacetin. | |
| 21:6.0.1.1.25.2.2.71 | SECTION 582.1973
| 582.1973 Beeswax. | |
| 21:6.0.1.1.25.2.2.72 | SECTION 582.1975
| 582.1975 Bleached beeswax. | |
| 21:6.0.1.1.25.2.2.73 | SECTION 582.1978
| 582.1978 Carnauba wax. | |
| 21:6.0.1.1.25.3 | SUBPART C
| Subpart C - Anticaking Agents | |
| 21:6.0.1.1.25.3.2.1 | SECTION 582.2122
| 582.2122 Aluminum calcium silicate. | |
| 21:6.0.1.1.25.3.2.2 | SECTION 582.2227
| 582.2227 Calcium silicate. | |
| 21:6.0.1.1.25.3.2.3 | SECTION 582.2437
| 582.2437 Magnesium silicate. | |
| 21:6.0.1.1.25.3.2.4 | SECTION 582.2727
| 582.2727 Sodium aluminosilicate. | |
| 21:6.0.1.1.25.3.2.5 | SECTION 582.2729
| 582.2729 Hydrated sodium calcium aluminosilicate. | |
| 21:6.0.1.1.25.3.2.6 | SECTION 582.2906
| 582.2906 Tricalcium silicate. | |
| 21:6.0.1.1.25.4 | SUBPART D
| Subpart D - Chemical Preservatives | |
| 21:6.0.1.1.25.4.2.1 | SECTION 582.3013
| 582.3013 Ascorbic acid. | |
| 21:6.0.1.1.25.4.2.2 | SECTION 582.3021
| 582.3021 Benzoic acid. | |
| 21:6.0.1.1.25.4.2.3 | SECTION 582.3041
| 582.3041 Erythorbic acid. | |
| 21:6.0.1.1.25.4.2.4 | SECTION 582.3081
| 582.3081 Propionic acid. | |
| 21:6.0.1.1.25.4.2.5 | SECTION 582.3089
| 582.3089 Sorbic acid. | |
| 21:6.0.1.1.25.4.2.6 | SECTION 582.3109
| 582.3109 Thiodipropionic acid. | |
| 21:6.0.1.1.25.4.2.7 | SECTION 582.3149
| 582.3149 Ascorbyl palmitate. | |
| 21:6.0.1.1.25.4.2.8 | SECTION 582.3169
| 582.3169 Butylated hydroxyanisole. | |
| 21:6.0.1.1.25.4.2.9 | SECTION 582.3173
| 582.3173 Butylated hydroxytoluene. | |
| 21:6.0.1.1.25.4.2.10 | SECTION 582.3189
| 582.3189 Calcium ascorbate. | |
| 21:6.0.1.1.25.4.2.11 | SECTION 582.3221
| 582.3221 Calcium propionate. | |
| 21:6.0.1.1.25.4.2.12 | SECTION 582.3225
| 582.3225 Calcium sorbate. | |
| 21:6.0.1.1.25.4.2.13 | SECTION 582.3280
| 582.3280 Dilauryl thiodipropionate. | |
| 21:6.0.1.1.25.4.2.14 | SECTION 582.3336
| 582.3336 Gum guaiac. | |
| 21:6.0.1.1.25.4.2.15 | SECTION 582.3490
| 582.3490 Methylparaben. | |
| 21:6.0.1.1.25.4.2.16 | SECTION 582.3616
| 582.3616 Potassium bisulfite. | |
| 21:6.0.1.1.25.4.2.17 | SECTION 582.3637
| 582.3637 Potassium metabisulfite. | |
| 21:6.0.1.1.25.4.2.18 | SECTION 582.3640
| 582.3640 Potassium sorbate. | |
| 21:6.0.1.1.25.4.2.19 | SECTION 582.3660
| 582.3660 Propyl gallate. | |
| 21:6.0.1.1.25.4.2.20 | SECTION 582.3670
| 582.3670 Propylparaben. | |
| 21:6.0.1.1.25.4.2.21 | SECTION 582.3731
| 582.3731 Sodium ascorbate. | |
| 21:6.0.1.1.25.4.2.22 | SECTION 582.3733
| 582.3733 Sodium benzoate. | |
| 21:6.0.1.1.25.4.2.23 | SECTION 582.3739
| 582.3739 Sodium bisulfite. | |
| 21:6.0.1.1.25.4.2.24 | SECTION 582.3766
| 582.3766 Sodium metabisulfite. | |
| 21:6.0.1.1.25.4.2.25 | SECTION 582.3784
| 582.3784 Sodium propionate. | |
| 21:6.0.1.1.25.4.2.26 | SECTION 582.3795
| 582.3795 Sodium sorbate. | |
| 21:6.0.1.1.25.4.2.27 | SECTION 582.3798
| 582.3798 Sodium sulfite. | |
| 21:6.0.1.1.25.4.2.28 | SECTION 582.3845
| 582.3845 Stannous chloride. | |
| 21:6.0.1.1.25.4.2.29 | SECTION 582.3862
| 582.3862 Sulfur dioxide. | |
| 21:6.0.1.1.25.4.2.30 | SECTION 582.3890
| 582.3890 Tocopherols. | |
| 21:6.0.1.1.25.5 | SUBPART E
| Subpart E - Emulsifying Agents | |
| 21:6.0.1.1.25.5.2.1 | SECTION 582.4101
| 582.4101 Diacetyl tartaric acid esters of mono- and diglycerides of edible fats or oils, or edible fat-forming fatty acids. | |
| 21:6.0.1.1.25.5.2.2 | SECTION 582.4505
| 582.4505 Mono- and diglycerides of edible fats or oils, or edible fat-forming acids. | |
| 21:6.0.1.1.25.5.2.3 | SECTION 582.4521
| 582.4521 Monosodium phosphate derivatives of mono- and diglycerides of edible fats or oils, or edible fat-forming fatty acids. | |
| 21:6.0.1.1.25.5.2.4 | SECTION 582.4666
| 582.4666 Propylene glycol. | |
| 21:6.0.1.1.25.6 | SUBPART F
| Subpart F - Nutrients and/or Dietary Supplements 1 | |
| 21:6.0.1.1.25.6.2.1 | SECTION 582.5013
| 582.5013 Ascorbic acid. | |
| 21:6.0.1.1.25.6.2.2 | SECTION 582.5017
| 582.5017 Aspartic acid. | |
| 21:6.0.1.1.25.6.2.3 | SECTION 582.5049
| 582.5049 Aminoacetic acid. | |
| 21:6.0.1.1.25.6.2.4 | SECTION 582.5065
| 582.5065 Linoleic acid. | |
| 21:6.0.1.1.25.6.2.5 | SECTION 582.5118
| 582.5118 Alanine. | |
| 21:6.0.1.1.25.6.2.6 | SECTION 582.5145
| 582.5145 Arginine. | |
| 21:6.0.1.1.25.6.2.7 | SECTION 582.5159
| 582.5159 Biotin. | |
| 21:6.0.1.1.25.6.2.8 | SECTION 582.5191
| 582.5191 Calcium carbonate. | |
| 21:6.0.1.1.25.6.2.9 | SECTION 582.5195
| 582.5195 Calcium citrate. | |
| 21:6.0.1.1.25.6.2.10 | SECTION 582.5201
| 582.5201 Calcium glycerophosphate. | |
| 21:6.0.1.1.25.6.2.11 | SECTION 582.5210
| 582.5210 Calcium oxide. | |
| 21:6.0.1.1.25.6.2.12 | SECTION 582.5212
| 582.5212 Calcium pantothenate. | |
| 21:6.0.1.1.25.6.2.13 | SECTION 582.5217
| 582.5217 Calcium phosphate. | |
| 21:6.0.1.1.25.6.2.14 | SECTION 582.5223
| 582.5223 Calcium pyrophosphate. | |
| 21:6.0.1.1.25.6.2.15 | SECTION 582.5230
| 582.5230 Calcium sulfate. | |
| 21:6.0.1.1.25.6.2.16 | SECTION 582.5245
| 582.5245 Carotene. | |
| 21:6.0.1.1.25.6.2.17 | SECTION 582.5250
| 582.5250 Choline bitartrate. | |
| 21:6.0.1.1.25.6.2.18 | SECTION 582.5252
| 582.5252 Choline chloride. | |
| 21:6.0.1.1.25.6.2.19 | SECTION 582.5260
| 582.5260 Copper gluconate. | |
| 21:6.0.1.1.25.6.2.20 | SECTION 582.5271
| 582.5271 Cysteine. | |
| 21:6.0.1.1.25.6.2.21 | SECTION 582.5273
| 582.5273 Cystine. | |
| 21:6.0.1.1.25.6.2.22 | SECTION 582.5301
| 582.5301 Ferric phosphate. | |
| 21:6.0.1.1.25.6.2.23 | SECTION 582.5304
| 582.5304 Ferric pyrophosphate. | |
| 21:6.0.1.1.25.6.2.24 | SECTION 582.5306
| 582.5306 Ferric sodium pyrophosphate. | |
| 21:6.0.1.1.25.6.2.25 | SECTION 582.5308
| 582.5308 Ferrous gluconate. | |
| 21:6.0.1.1.25.6.2.26 | SECTION 582.5311
| 582.5311 Ferrous lactate. | |
| 21:6.0.1.1.25.6.2.27 | SECTION 582.5315
| 582.5315 Ferrous sulfate. | |
| 21:6.0.1.1.25.6.2.28 | SECTION 582.5361
| 582.5361 Histidine. | |
| 21:6.0.1.1.25.6.2.29 | SECTION 582.5370
| 582.5370 Inositol. | |
| 21:6.0.1.1.25.6.2.30 | SECTION 582.5375
| 582.5375 Iron reduced. | |
| 21:6.0.1.1.25.6.2.31 | SECTION 582.5381
| 582.5381 Isoleucine. | |
| 21:6.0.1.1.25.6.2.32 | SECTION 582.5406
| 582.5406 Leucine. | |
| 21:6.0.1.1.25.6.2.33 | SECTION 582.5411
| 582.5411 Lysine. | |
| 21:6.0.1.1.25.6.2.34 | SECTION 582.5431
| 582.5431 Magnesium oxide. | |
| 21:6.0.1.1.25.6.2.35 | SECTION 582.5434
| 582.5434 Magnesium phosphate. | |
| 21:6.0.1.1.25.6.2.36 | SECTION 582.5443
| 582.5443 Magnesium sulfate. | |
| 21:6.0.1.1.25.6.2.37 | SECTION 582.5446
| 582.5446 Manganese chloride. | |
| 21:6.0.1.1.25.6.2.38 | SECTION 582.5449
| 582.5449 Manganese citrate. | |
| 21:6.0.1.1.25.6.2.39 | SECTION 582.5452
| 582.5452 Manganese gluconate. | |
| 21:6.0.1.1.25.6.2.40 | SECTION 582.5455
| 582.5455 Manganese glycerophosphate. | |
| 21:6.0.1.1.25.6.2.41 | SECTION 582.5458
| 582.5458 Manganese hypophosphite. | |
| 21:6.0.1.1.25.6.2.42 | SECTION 582.5461
| 582.5461 Manganese sulfate. | |
| 21:6.0.1.1.25.6.2.43 | SECTION 582.5464
| 582.5464 Manganous oxide. | |
| 21:6.0.1.1.25.6.2.44 | SECTION 582.5470
| 582.5470 Mannitol. | |
| 21:6.0.1.1.25.6.2.45 | SECTION 582.5475
| 582.5475 Methionine. | |
| 21:6.0.1.1.25.6.2.46 | SECTION 582.5477
| 582.5477 Methionine hydroxy analog and its calcium salts. | |
| 21:6.0.1.1.25.6.2.47 | SECTION 582.5530
| 582.5530 Niacin. | |
| 21:6.0.1.1.25.6.2.48 | SECTION 582.5535
| 582.5535 Niacinamide. | |
| 21:6.0.1.1.25.6.2.49 | SECTION 582.5580
| 582.5580 D-Pantothenyl alcohol. | |
| 21:6.0.1.1.25.6.2.50 | SECTION 582.5590
| 582.5590 Phenylalanine. | |
| 21:6.0.1.1.25.6.2.51 | SECTION 582.5622
| 582.5622 Potassium chloride. | |
| 21:6.0.1.1.25.6.2.52 | SECTION 582.5628
| 582.5628 Potassium glycerophosphate. | |
| 21:6.0.1.1.25.6.2.53 | SECTION 582.5634
| 582.5634 Potassium iodide. | |
| 21:6.0.1.1.25.6.2.54 | SECTION 582.5650
| 582.5650 Proline. | |
| 21:6.0.1.1.25.6.2.55 | SECTION 582.5676
| 582.5676 Pyridoxine hydrochloride. | |
| 21:6.0.1.1.25.6.2.56 | SECTION 582.5695
| 582.5695 Riboflavin. | |
| 21:6.0.1.1.25.6.2.57 | SECTION 582.5697
| 582.5697 Riboflavin-5-phosphate. | |
| 21:6.0.1.1.25.6.2.58 | SECTION 582.5701
| 582.5701 Serine. | |
| 21:6.0.1.1.25.6.2.59 | SECTION 582.5772
| 582.5772 Sodium pantothenate. | |
| 21:6.0.1.1.25.6.2.60 | SECTION 582.5778
| 582.5778 Sodium phosphate. | |
| 21:6.0.1.1.25.6.2.61 | SECTION 582.5835
| 582.5835 Sorbitol. | |
| 21:6.0.1.1.25.6.2.62 | SECTION 582.5875
| 582.5875 Thiamine hydrochloride. | |
| 21:6.0.1.1.25.6.2.63 | SECTION 582.5878
| 582.5878 Thiamine mononitrate. | |
| 21:6.0.1.1.25.6.2.64 | SECTION 582.5881
| 582.5881 Threonine. | |
| 21:6.0.1.1.25.6.2.65 | SECTION 582.5890
| 582.5890 Tocopherols. | |
| 21:6.0.1.1.25.6.2.66 | SECTION 582.5892
| 582.5892 a-Tocopherol acetate. | |
| 21:6.0.1.1.25.6.2.67 | SECTION 582.5915
| 582.5915 Tryptophane. | |
| 21:6.0.1.1.25.6.2.68 | SECTION 582.5920
| 582.5920 Tyrosine. | |
| 21:6.0.1.1.25.6.2.69 | SECTION 582.5925
| 582.5925 Valine. | |
| 21:6.0.1.1.25.6.2.70 | SECTION 582.5930
| 582.5930 Vitamin A. | |
| 21:6.0.1.1.25.6.2.71 | SECTION 582.5933
| 582.5933 Vitamin A acetate. | |
| 21:6.0.1.1.25.6.2.72 | SECTION 582.5936
| 582.5936 Vitamin A palmitate. | |
| 21:6.0.1.1.25.6.2.73 | SECTION 582.5945
| 582.5945 Vitamin B12. | |
| 21:6.0.1.1.25.6.2.74 | SECTION 582.5950
| 582.5950 Vitamin D2. | |
| 21:6.0.1.1.25.6.2.75 | SECTION 582.5953
| 582.5953 Vitamin D3. | |
| 21:6.0.1.1.25.6.2.76 | SECTION 582.5985
| 582.5985 Zinc chloride. | |
| 21:6.0.1.1.25.6.2.77 | SECTION 582.5988
| 582.5988 Zinc gluconate. | |
| 21:6.0.1.1.25.6.2.78 | SECTION 582.5991
| 582.5991 Zinc oxide. | |
| 21:6.0.1.1.25.6.2.79 | SECTION 582.5994
| 582.5994 Zinc stearate. | |
| 21:6.0.1.1.25.6.2.80 | SECTION 582.5997
| 582.5997 Zinc sulfate. | |
| 21:6.0.1.1.25.7 | SUBPART G
| Subpart G - Sequestrants 2 | |
| 21:6.0.1.1.25.7.2.1 | SECTION 582.6033
| 582.6033 Citric acid. | |
| 21:6.0.1.1.25.7.2.2 | SECTION 582.6085
| 582.6085 Sodium acid phosphate. | |
| 21:6.0.1.1.25.7.2.3 | SECTION 582.6099
| 582.6099 Tartaric acid. | |
| 21:6.0.1.1.25.7.2.4 | SECTION 582.6185
| 582.6185 Calcium acetate. | |
| 21:6.0.1.1.25.7.2.5 | SECTION 582.6193
| 582.6193 Calcium chloride. | |
| 21:6.0.1.1.25.7.2.6 | SECTION 582.6195
| 582.6195 Calcium citrate. | |
| 21:6.0.1.1.25.7.2.7 | SECTION 582.6197
| 582.6197 Calcium diacetate. | |
| 21:6.0.1.1.25.7.2.8 | SECTION 582.6199
| 582.6199 Calcium gluconate. | |
| 21:6.0.1.1.25.7.2.9 | SECTION 582.6203
| 582.6203 Calcium hexametaphosphate. | |
| 21:6.0.1.1.25.7.2.10 | SECTION 582.6215
| 582.6215 Monobasic calcium phosphate. | |
| 21:6.0.1.1.25.7.2.11 | SECTION 582.6219
| 582.6219 Calcium phytate. | |
| 21:6.0.1.1.25.7.2.12 | SECTION 582.6285
| 582.6285 Dipotassium phosphate. | |
| 21:6.0.1.1.25.7.2.13 | SECTION 582.6290
| 582.6290 Disodium phosphate. | |
| 21:6.0.1.1.25.7.2.14 | SECTION 582.6386
| 582.6386 Isopropyl citrate. | |
| 21:6.0.1.1.25.7.2.15 | SECTION 582.6511
| 582.6511 Monoisopropyl citrate. | |
| 21:6.0.1.1.25.7.2.16 | SECTION 582.6625
| 582.6625 Potassium citrate. | |
| 21:6.0.1.1.25.7.2.17 | SECTION 582.6751
| 582.6751 Sodium citrate. | |
| 21:6.0.1.1.25.7.2.18 | SECTION 582.6754
| 582.6754 Sodium diacetate. | |
| 21:6.0.1.1.25.7.2.19 | SECTION 582.6757
| 582.6757 Sodium gluconate. | |
| 21:6.0.1.1.25.7.2.20 | SECTION 582.6760
| 582.6760 Sodium hexametaphosphate. | |
| 21:6.0.1.1.25.7.2.21 | SECTION 582.6769
| 582.6769 Sodium metaphosphate. | |
| 21:6.0.1.1.25.7.2.22 | SECTION 582.6778
| 582.6778 Sodium phosphate. | |
| 21:6.0.1.1.25.7.2.23 | SECTION 582.6787
| 582.6787 Sodium pyrophosphate. | |
| 21:6.0.1.1.25.7.2.24 | SECTION 582.6789
| 582.6789 Tetra sodium pyrophosphate. | |
| 21:6.0.1.1.25.7.2.25 | SECTION 582.6801
| 582.6801 Sodium tartrate. | |
| 21:6.0.1.1.25.7.2.26 | SECTION 582.6804
| 582.6804 Sodium potassium tartrate. | |
| 21:6.0.1.1.25.7.2.27 | SECTION 582.6807
| 582.6807 Sodium thiosulfate. | |
| 21:6.0.1.1.25.7.2.28 | SECTION 582.6810
| 582.6810 Sodium tripolyphosphate. | |
| 21:6.0.1.1.25.7.2.29 | SECTION 582.6851
| 582.6851 Stearyl citrate. | |
| 21:6.0.1.1.25.8 | SUBPART H
| Subpart H - Stabilizers | |
| 21:6.0.1.1.25.8.2.1 | SECTION 582.7115
| 582.7115 Agar-agar. | |
| 21:6.0.1.1.25.8.2.2 | SECTION 582.7133
| 582.7133 Ammonium alginate. | |
| 21:6.0.1.1.25.8.2.3 | SECTION 582.7187
| 582.7187 Calcium alginate. | |
| 21:6.0.1.1.25.8.2.4 | SECTION 582.7255
| 582.7255 Chondrus extract. | |
| 21:6.0.1.1.25.8.2.5 | SECTION 582.7330
| 582.7330 Gum arabic. | |
| 21:6.0.1.1.25.8.2.6 | SECTION 582.7333
| 582.7333 Gum ghatti. | |
| 21:6.0.1.1.25.8.2.7 | SECTION 582.7339
| 582.7339 Guar gum. | |
| 21:6.0.1.1.25.8.2.8 | SECTION 582.7343
| 582.7343 Locust bean gum. | |
| 21:6.0.1.1.25.8.2.9 | SECTION 582.7349
| 582.7349 Sterculia gum. | |
| 21:6.0.1.1.25.8.2.10 | SECTION 582.7351
| 582.7351 Gum tragacanth. | |
| 21:6.0.1.1.25.8.2.11 | SECTION 582.7610
| 582.7610 Potassium alginate. | |
| 21:6.0.1.1.25.8.2.12 | SECTION 582.7724
| 582.7724 Sodium alginate. | |
| 21:6.0.1.1.26 | PART 584
| PART 584 - FOOD SUBSTANCES AFFIRMED AS GENERALLY RECOGNIZED AS SAFE IN FEED AND DRINKING WATER OF ANIMALS | |
| 21:6.0.1.1.26.1 | SUBPART A
| Subpart A [Reserved] | |
| 21:6.0.1.1.26.2 | SUBPART B
| Subpart B - Listing of Specific Substances Affirmed as GRAS | |
| 21:6.0.1.1.26.2.2.1 | SECTION 584.200
| 584.200 Ethyl alcohol containing ethyl acetate. | |
| 21:6.0.1.1.26.2.2.2 | SECTION 584.700
| 584.700 Hydrophobic silicas. | |
| 21:6.0.1.1.26.2.2.3 | SECTION 584.725
| 584.725 25-Hydroxyvitamin D3. | |
| 21:6.0.1.1.27 | PART 589
| PART 589 - SUBSTANCES PROHIBITED FROM USE IN ANIMAL FOOD OR FEED | |
| 21:6.0.1.1.27.1 | SUBPART A
| Subpart A - General Provisions | |
| 21:6.0.1.1.27.1.2.1 | SECTION 589.1
| 589.1 Substances prohibited from use in animal food or feed. | |
| 21:6.0.1.1.27.2 | SUBPART B
| Subpart B - Listing of Specific Substances Prohibited From Use in Animal Food or Feed | |
| 21:6.0.1.1.27.2.2.1 | SECTION 589.1000
| 589.1000 Gentian violet. | |
| 21:6.0.1.1.27.2.2.2 | SECTION 589.1001
| 589.1001 Propylene glycol in or on cat food. | |
| 21:6.0.1.1.27.2.2.3 | SECTION 589.2000
| 589.2000 Animal proteins prohibited in ruminant feed. | |
| 21:6.0.1.1.27.2.2.4 | SECTION 589.2001
| 589.2001 Cattle materials prohibited in animal food or feed to prevent the transmission of bovine spongiform encephalopathy. | |
| 21:6.0.1.1.28 | PART 590-599
| PARTS 590-599 [RESERVED] | |